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NEAA    Non essential amino acids 
OATP    Organic anion transporting polypeptide 
OCT    Organic cation transporter 
OCTN    Carnitine/organic cation transporter 
PCR    Polymerase chain reaction 
PBS    Phosphate buffered saline 
PXR    Pregnane X receptor 
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RXR    Retinoic X receptor 
SCA Cn   Short-chain-acylcarnitine 
SCD    Systemic Carnitine Deficiency 
SRB    Sulforhodamine B 
SV40Tag   Simian virus 40 large T antigen 
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WEM    Williams E Medium 
WT    Wild type 
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zVAD-fmk   Z-Val-Ala-Asp-fluoromethylketone 
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3 Summary 
 
The liver is the primary site of drug metabolism and plays a major role in metabolism, 
digestion, detoxification, and elimination of drugs and toxins from the body. 
Consequently, drugs affect the liver more frequently than any other organ and place 
the liver at increased risk for toxic damage. Drug-induced liver injury (DILI) is a 
common cause of acute liver failure and the most frequent reason for the withdrawal 
of approved drugs, representing a serious challenge for the pharmaceutical industry. 
The risk of developing hepatotoxicity is not only due to the chemical properties of the 
drug but also to environmental factors, pre-existing diseases and genetic factors, 
leading to the classification into either predictable (high incidence) or unpredictable 
(low incidence) hepatotoxicity. Drugs that produce predictable liver injury are 
generally a result of direct liver toxicity of the parent drug or its metabolites. However, 
the majority of adverse drug-induced hepatic events are unpredictable and the 
underlying mechanisms are mostly unknown, but assumed to be either immune-
mediated hypersensitivity reactions or idiosyncratic and are able to alter the 
susceptibility to adverse events. In recent years mitochondrial dysfunction has been 
recognized as β-oxidation of fatty acids, inhibition or uncoupling of the respiratory 
chain, or through a primary effect on the mitochondrial genome. 
 
One aim of this thesis was to investigate the juvenile visceral steatosis (jvs) mouse, 
which is characterized by microvesicular steatosis of the liver and to impaired renal 
reabsorption leading to systemic carnitine deficiency. The main focus was put on the 
assessment of the hepatic toxicity of valproate, an antiepileptic drug known to induce 
liver injury, and to investigate whether the underlying carnitine deficiency is a risk 
factor for valproate-associated hepatotoxicity. Furthermore, in vitro studies using 
several hepatic cell lines were performed to estimate the suitability as screening 
systems for hepatic metabolism and CYP induction, and one study was conducted to 
evaluate the hepatotoxic effect of the plant cimicifuga racemosa. 
 
Initially we assessed the carnitine homeostasis and energy metabolism in carnitine-
deficient (jvs-/-) mice after cessation of carnitine substitution (Chapter 6). It is well 
established that sufficient carnitine plasma and tissue levels in jvs mice can be 
obtained by carnitine substitution, correcting carnitine deficiency. We studied the 
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kinetics of carnitine loss from plasma and tissue carnitine stores and markers of 
energy metabolism after carnitine deprivation for a maximum of ten days. The total 
carnitine concentrations in plasma, liver and skeletal muscle were significantly 
decreased, whereas carnitine concentration decreased rapidly in plasma but much 
slower in tissue. Deprivation of carnitine was also associated with a further drop in 
the plasma β-hydroxybutyrate levels and hepatic fat accumulation. 
 
In a second in vivo experiment (Chapter7) we investigated whether carnitine 
deficiency is a risk factor for valproate-associated hepatotoxicity in jvs mice, and we 
assessed the effects of valproate on carnitine plasma and tissue stores in these 
mice. Therefore, we treated heterozygous jvs+/- and the corresponding wild type 
mice with subtoxic oral doses of valproate for two weeks. Our study shows that jvs+/- 
mice treated with VPA have impaired hepatic mitochondrial β-oxidation and 
increased hepatic fat accumulation, findings associated with increased activities of 
serum transaminases and alkaline phosphatase, and hepatocellular damage. 
Furthermore, the effect of VPA treatment on the carnitine plasma and tissue stores 
was much more dramatic in JVS+/- than in wild type mice, leading to additional and 
substantial losses in the plasma and tissue carnitine pools. In conclusion, hepatic 
toxicity of VPA was more pronounced in JVS+/- mice than in corresponding wild type 
mice, and systemic carnitine deficiency can therefore be considered to be a risk 
factor for hepatotoxicity associated with VPA.  
 
In an in vitro study using hepatic cell lines (Chapter 8), drug-induced changes in the 
activity of cytochrome P450 isoforms were assessed. Since the activity of most CYPs 
can be regulated by induction and/or inhibition by specific drugs, and possibly 
affecting the metabolism of other drugs or even their own metabolism, we 
investigated the expression and induction of several CYP isozymes and the human 
pregnane X receptor in immortalized human hepatocytes for their suitability as 
screening systems for hepatic drug metabolism. Our investigations demonstrated that 
hHepLT5 cells contain the main human CYP isozymes CYP1A2 and CYP3A4 which 
are important for drug metabolism. Summarized, hHepLT5 cells appear therefore to 
be a valuable alternative for primary human hepatocytes for studying pharmaco-
logical and toxicological features of new drug entities.  
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The last described study (Chapter 9) was conducted to assess the hepatotoxicity of 
cimicifuga racemosa in experimental animals in vivo, in hepatocyte cultures and in 
isolated liver mitochondria. Ethanolic cimicifuga racemosa extract was administered 
orally to rats and liver sections were analyzed for microvesicular steatosis by electron 
microscopy. Tests for cytotoxicity, mitochondrial toxicity and apoptosis/necrosis were 
performed using HepG2 cells, and mitochondrial toxicity was studied using isolated 
rat liver mitochondria. The main findings in vivo and in vitro were hepatic 
mitochondrial toxicity, as evidenced by microvesicular steatosis and inhibition of β-
oxidation, eventually resulting in apoptotic cell death. These findings suggest that 
inhibition of β-oxidation is the initial hepatotoxic event of cimicifuga extract, which 
eventually may result in apoptosis of the hepatocytes.  
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4 Aim of the thesis 
 
The major purpose was to characterize in vitro and in vivo systems for the evaluation 
of drug-induced hepatotoxicity. For in vivo experiments we used a mouse model with 
systemic carnitine to estimate whether a pre-existing mitochondrial dysfunction due 
to inhibition of the β-oxidation of fatty acids represents a risk factor for susceptibility 
to drug-induced hepatotoxicity. In vitro studies were performed with hepatic cell lines, 
namely hepatocellular carcinoma cells and immortalized human hepatocytes. These 
cells were characterized by studying the expression and induction of drug 
metabolizing enzymes as a useful tool to study the hepatic metabolism of different 
drugs and for toxicological investigations.  
 
Summarized, the following issues were studied: 
 
I) Carnitine homeostasis and energy metabolism in carnitine-deficient (jvs-/-) 
mice after cessation of carnitine substitution 
 
II) Toxicity of valproic acid in jvs mice with impaired β-oxidation associated 
with carnitine deficiency 
 
III) Expression and inducibility of cytochrome P450 isozymes in immortalized 
human hepatocytes 
 
IV) Hepatotoxic effects of cimicifuga racemosa (black cohosh). 
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5 Introduction 
5.1 In vivo investigations 
5.1.1 Carnitine – Functions 
 
Carnitine (β-hydroxy-4-N-trimethylaminobutyric acid) has several important intra-
cellular functions.  
Primarily, it represents an essential cofactor for the transport of activated long-chain 
fatty acids across the inner mitochondrial membrane to the mitochondrial matrix 
(Figure 2), where β-oxidation takes place (Bremer, 1983; Rebouche and Paulson, 
1986). Cytosolic long-chain fatty acids, which are present as CoA esters, are 
activated by a specific acyl-CoA synthase at the outer mitochondrial membrane. The 
long-chain acyl-CoAs (e.g. palmitoyl-CoA) are further conjugated to carnitine by 
carnitine palmitoyltransferase I (CPT I). The resulting long-chain acylcarnitine esters 
are transported over the inner mitochondrial membrane via the specific carrier 
carnitine-acylcarnitine translocase (CACT) and reconverted to long-chain acyl-CoAs 
in the mitochondrial matrix by carnitine palmitoyltransferase II (CPTII). In the 
mitochondria, the long-chain acyl-CoAs undergo β-oxidation, resulting in the 
production of acetyl-CoA. Short and medium-chain acyl-CoAs can be reconverted 
into acylcarnitines by the enzyme carnitine acetyltransferase (CAT) and can then 
leave the mitochondria via CACT for another round of transport.  
 
Carnitine plays also an important role in the transfer of products of the peroxisomal β-
oxidation, e.g. acetyl-CoA, to the mitochondria for the oxidation to CO2 and H20 in 
the Krebs cycle (Wanders et al., 1995). Other functions of carnitine include the 
modulation of the free CoA/acyl-CoA ratio, the storage of energy as acetylcarnitine 
and the detoxification of potentially toxic, poorly metabolized acyl groups by excreting 
them as carnitine esters (Bremer, 1983; Bieber, 1988; Steiber et al., 2004). 
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Figure1: Function of carnitine in the transport of mitochondrial long-chain fatty acid oxidation and 
regulation of the intramitochondrial free CoA/acyl CoA ratio 
 
 
5.1.2 Carnitine – Biosynthesis 
 
 
 
Figure 2: L-Carnitine 
 
 
Carnitine, a water-soluble zwitterion, is a chemically simple substance, physiologi-
cally presented as L-enantiomer and containing a negatively charged carboxylate at 
C1 and a positively charged quaternary nitrogen at C4 at physiological pH (Figure 2). 
Most of the carnitine needed is obtained from the diet, in particular by meat and dairy 
products. The rest is biosynthesized, starting from the amino acids lysine and 
methionine, whereas lysine provides the carbon backbone and the 4-N-methyl 
groups originate from methionine (Tanphaichitr et al., 1971; Horne and Broquist, 
1973).  
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Figure 3: Pathway of carnitine biosynthesis 
 
 
In mammals, the carnitine biosynthesis is initiated by the N-methylation of the protein 
linked L-lysine. This reaction is catalyzed by specific methyltransferases, which use 
S-adenosyl-L-methionine as a methyl donor (Paik and Kim, 1971; Cox and Hoppel, 
1973). Lysosomal hydrolysis of these proteins results in the release of 6-N-trimethyl-
lysine (TML), the first metabolite of carnitine biosynthesis (LaBadie et al., 1976; Dunn 
and Englard, 1981). The following hydroxylation on the 3-position by TML 
dioxygenase (TMLD) yields 3-hydroxy-TML (HTML), which is cleaved to 4-
trimethylaminobutyraldehyde (TMABA) and glycine, a reaction catalysed by the 
HTML aldolase (HTMLA). Dehydrogenation of TMABA by the TMABA 
dehydrogenase (TMABA-DH) results in the formation of 4-N-trimethylaminobutyrate 
(butyrobetaine). In the last step, butyrobetaine is hydroxylated on the 3-position by γ-
butyrobetaine dioxygenase (BBD). Human skeletal muscle, heart, liver, kidney and 
brain are capable to the biosynthesis of carnitine from methionine and lysine to its 
immediate precursor γ-butyrobetaine (Rebouche and Engel, 1980). Final conversion 
of γ-butyrobetaine to L-carnitine by γ-butyrobetaine hydroxylase can only be done in 
liver, kidney and brain in humans (Englard, 1979). The chemical structure of the 
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intermediates and the enzymes of the carnitine biosynthesis are shown in Figure 3 
and 4. 
 
 
 
 
 
Figure 4: Metabolites of the carnitine biosynthesis 
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5.1.3 Carnitine – Absorption, Metabolism and Elimination  
In omnivores, approximately 75% of carnitine sources are from the diet and about 
25% from endogenous synthesis, whereas in strict vegetarians, endogenous 
carnitine synthesis provides >90% of the total available carnitine (Rebouche, 1992). 
Carnitine homeostasis in mammals is maintained by a combination of absorption of 
carnitine from dietary sources, a modest rate of endogenous synthesis, efficient 
reabsorption from the glomerular, and mechanisms present in most tissues that 
establish and maintain substantial concentration gradients between intracellular and 
extracellular carnitine pools. The rate of carnitine biosynthesis in humans is 
estimated to be about 1.2 µmol per kg body weight per day, which was evaluated 
from the steady-state rate of excretion of carnitine by strict vegetarian adults and 
children (Lombard et al., 1989). The major dietary sources of carnitine are meat, 
poultry, fish and dairy products (Rebouche and Engel, 1984). An average 
omnivorous diet provide 2 to 12 µmol of carnitine per kilogram of body weight per 
day, in contrast to strict vegetarians consuming less than 0.1 µmol of carnitine per 
kilogram of body weight per day. Skeletal muscle contains over 90% of total body 
carnitine (Rebouche, 1992), and the plasma carnitine concentration is regulated 
largely by the renal threshold, which is approximately 40 µmol/l (Engel et al., 1981).  
Since carnitine is found in very high concentrations in skeletal muscle, heart and 
epididymal fluid – tissues that lack the ability to synthesize carnitine - it is obvious 
that an active transport takes place, which has been reported to be sodium 
dependent (Rebouche and Mack, 1984). Absorption of carnitine results from a two-
component system, namely a linear absorption, probably representing a passive 
diffusion, and a saturable system suggesting the presence of an active transport 
system (Hamilton et al., 1986). Additionally, carnitine absorption was shown to be 
dependent on the intake amount, whereas humans do not absorb all of the 
consumed carnitine, proving the theory that a specific active transporter, which can 
be saturated even with a normal dietary intake, might be involved (Harper et al., 
1988). 
It has been shown that carnitine is extensively metabolized in microorganisms, 
whereas bacteria are able to metabolize the trimethylammonium compound of 
carnitine in three different ways. Depending on the species and the cultivation 
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conditions used (e.g. aerobiosis, anaerobiosis) L-carnitine is catabolized by various 
pathways. Some, especially Pseudomonas species, assimilate carnitine as a unique 
source of carbon and nitrogen. The first catabolic step is the oxidation of the β-
hydroxy group of carnitine with formation of 3-dehydrocarnitine, which is catalyzed by 
the L-carnitine dehydrogenase. 3-dehydrocarnitine is degraded to glycine betaine 
and further metabolized by step demethylation to glycine (Lindstedt et al., 1970; 
Kleber, 1997). Others, for instance, Acinetobacter species are able to degrade only 
the carbon backbone of L-carnitine with formation of trimethylamine (Kleber et al., 
1977). A third group of carnitine metabolizing microorganisms comprises different 
Enterobacteriaccae. These bacteria have the ability to metabolize L-carnitine, via 
crotonbetaine, to γ-butyrobetaine in the presence of carbon and nitrogen sources 
during anaerobic growth (Seim et al., 1980). 
In contrast to microorganisms, mammals lack the enzymes which are responsible for 
the degradation of carnitine (Rebouche et al., 1984; Seim et al., 1985). It was shown, 
after oral administration of radioactive-labeled carnitine in rats, that urine and feces 
contained two radiolabeled metabolites which were identified as trimethylamine N-
oxide and γ-butyrobetaine. For rats that received intravenous labelled carnitine or 
germ-free rats receiving the isotope orally or intravenously, the radioactivity 
recovered was in the form of carnitine and the mentioned metabolites were not found 
(Rebouche et al., 1984; Seim et al., 1985). It was concluded that the indigenous flora, 
but not the tissues of mammals, is responsible for carnitine degradation in the 
gastrointestinal tract. Same results were found in human studies, in which a tracer 
dose of radioactive-labeled carnitine was administered orally. The major metabolites 
found were trimethylamine N-oxide (primarily in urine) and γ-butyrobetaine (primarily 
in feces), whereas the formation of these metabolites was attributed to the bacterial 
flora in the gastrointestinal tract of humans (Rebouche and Chenard, 1991). 
 
Under normal homeostasis conditions, carnitine is mainly eliminated by excretion in 
urine. In rats, 1 to 2 µmol of carnitine is excreted per 100 g body weight per day, 
whereas this amount represents 5 to 7% of the total body pool (Cederblad and 
Lindstedt, 1976; Brass and Hoppel, 1978). In these animals, the glomerular filtration 
rate is about 5 liters per day, contrary to the carnitine clearance with only 5 ml per 
day, which implies that 99.9% of the filtered carnitine is reabsorbed in the kidney 
(Brass and Hoppel, 1978). In healthy humans, the serum clearance of carnitine is 
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about 1 ml per day, the daily excretion in urine is 100 to 300 µmol and the tubular 
reabsorption in the kidney is 90 to 98% (Maebashi et al., 1976). In strict vegetarians, 
dietary carnitine supplementation did not significantly increase plasma carnitine 
concentration and did not alter the glomerular filtration rate. At normal physiological 
plasma carnitine concentrations, the rate of carnitine excretion was increased and the 
rate of carnitine reabsorption was decreased by carnitine supplementation. It was 
concluded that the kidney adapts to carnitine intake by reducing the efficiency of 
carnitine reabsorption (Rebouche et al., 1993). Excretion of carnitine also takes place 
into milk, whereas the carnitine concentration was shown to increase in the first week 
post-partum from 39 to 63 µmol/l and was stabilized at 45 µmol/l after one month 
(Borum, 1981). 
 
 
5.1.4 Carnitine – Transport 
 
Since the cloning of the first organic cation transporter OCT1 from rat kidney in 1994 
many of other transport members belonging to the OCT family have been described. 
A subfamily of the organic cation transporter family, namely the carnitine/organic 
cation OCTN transporters have been isolated and characterized in mice (Tamai et 
al., 2000). The members include the low affinity transporter OCTN1, the high affinity 
transporter OCTN2 and the intermediate affinity transporter OCTN3, which have the 
ability to transport carnitine, but with variable characteristics. The primary function of 
these transporters is the elimination of cationic drugs and other xenobiotics. Carnitine 
transport through cation transporters has a pharmacological importance since the 
OCTN2 transports drugs such as valproate, verapamil and quinidine (Wu et al., 
1999). 
OCTN1, originally cloned from a human fetal kidney library, is widely expressed in 
various tissues (Tamai et al., 1997). Rat OCTN1, cloned from placenta, is expressed 
particularly in liver, intestine, kidney, brain and placenta. There is a very low affinity 
interaction between carnitine and rat OCTN1, and this transporter does not mediate 
Na+-coupled carnitine transport to a significant extent (Wu et al., 2000). However, 
mouse OCTN1 can mediate carnitine transport in a Na+-dependent manner, 
illustrating an apparent species difference in the specifity for the same transporter 
type (Tamai et al., 2000).  
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OCTN2 was first isolated from a human placental trophoblast cell line (Wu et al., 
1998) and from a human kidney cDNA library (Tamai et al., 1998). This transporter is 
widely expressed in human tissues such as heart, skeletal muscle, kidney, placenta, 
small intestine and some brain areas (Tamai et al., 1998; Wu et al., 1998; Wu et al., 
1999). OCTN2 functions as a Na+-dependent carnitine transporter as well as Na+-
independent transporter for other organic cations. The Na+-dependent L-carnitine 
transport by OCTN2 is done with high affinity with the apparent Km value of 4.3 µM 
(Tamai et al., 1998). Several anionic drugs such as valproate, as well as cationic 
drugs (e.g. verapamil, emetine) and short-chain acyl esters of carnitine (e.g. acetyl-L-
carntine), used as therapeutic agents in the treatment of a wide range of disorders, 
are also transported by OCTN2 (Wu et al., 1999) and consequently inhibit the 
OCTN2-mediated carnitine uptake (Figure 5). 
 
 
 
Figure 5: Therapeutic uses of carnitine and certain organic cation drugs transported by OCTN2 
 
 
 
The last member of the OCTN family is termed OCTN3 and was isolated from mice. 
The mouse OCTN3 was expressed predominantly in testis and weakly in kidney. 
Functionally, mouse OCTN3 mediates carnitine transport in a Na+-independent 
manner, contrary to mouse OCTN1 and OCTN2 which transport carnitine in a Na+-
dependent mode, and additionally, OCTN3 has a higher specificity for carnitine 
transport than OCTN1 and OCTN2 (Tamai et al., 2000). 
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5.1.5 Mutations in OCTN2 
 
The physiological significance of the transporters in the body is confirmed by the 
identification of hereditary diseases caused by mutations of genes encoding various 
transporters (Sesaki, 2000). In the case of OCTN2, the ultimate proof of its 
importance derives from mutations in the gene encoding the protein, which cause an 
autosomal recessive disease named primary systemic carnitine deficiency (SCD) 
(Nezu et al., 1999). There are numerous studies describing patients with nonsense or 
missense mutations in OCTN2 and different clinical manifestations. In SCD 
homozygous patients, who manifest symptoms like cardiomyopathy, progressive 
skeletal weakness, non-ketotic hypoglycaemia and hyperammonemia, many 
mutations in the OCTN2 protein have been identified (Figure 6). 
 
 
 
Figure 6: Mutations in the carnitine/organic cation transporter OCTN2 in humans 
 
 
 
5.1.6 Systemic Carnitine Deficiency 
 
Carnitine deficiency can be characterized by low plasma and tissue carnitine 
concentrations and can be defined as a decrease of intracellular carnitine, leading to 
an accumulation of acyl-CoA esters and an inhibition of acyl-transport via the 
mitochondrial inner membrane. Due to the two main functions of carnitine, namely 
the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation 
to provide cellular energy and the modulation of the rise in intramitochondrial acyl-
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CoA/CoA ratio, which relieves the inhibition of many intramitochondrial enzymes, the 
main consequence of carnitine deficiency is impaired energy metabolism and 
pathological changes in different tissues such as liver, muscle, heart and brain (Engel 
and Angelini, 1973; Karpati et al., 1975; Pons and De Vivo, 1995). Since the first 
description of human myopathic carnitine deficiency (Engel and Angelini, 1973), 
different forms of carnitine deficiency have been reported. According to their different 
ethiologies, human carnitine deficiency can be either hereditary or acquired. 
Hereditary carnitine deficiency can be grouped into three clinical entities: myopathic 
carnitine deficiency, systemic carnitine deficiency, and organic acidurias. Acquired 
carnitine deficiency is due to inadequate intake, increased requirement, and 
increased loss of carnitine (Angelini et al., 1992; Kerner and Hoppel, 1998).  
 
5.1.6.1 Primary Carnitine Deficiency 
 
Primary carnitine deficiency is defined as a decrease in intracellular carnitine content, 
which is associated with impaired fatty acid oxidation and with no other identifiable 
systemic disease that might deplete tissue carnitine stores (Millington and Roe, 
1989). There are two forms of primary carnitine deficiency, depending on the tissue 
distribution of the low carnitine level: The systemic carnitine deficiency with low 
carnitine levels in plasma and the affected tissues, and the muscle carnitine 
deficiency, with low carnitine concentration restricted to muscle (Engel and Angelini, 
1973; Karpati et al., 1975). 
 
I. Systemic Carnitine Deficiency (SCD) 
 
Primary systemic carnitine deficiency (SCD; OMIM 212140) is an autosomal 
recessive disorder characterized by progressive cardiomyopathy, skeletal myopathy 
hypoglycaemia and hyperammonemia (Karpati et al., 1975; Treem et al., 1988). It 
was first described in 1975 (Karpati et al., 1975), and is differentiated from myopathic 
carnitine deficiency (OMIM 212160). The defects in this disorder result from an 
impaired carnitine uptake into cells and are associated with a deficient renal carnitine 
transporter (Treem et al., 1988). There have been identified numerous point 
mutations in the gene encoding for the high affinity carnitine transporter OCTN2 in 
SCD patients (Nezu et al., 1999; Tang et al., 1999; Vaz et al., 1999; Wang et al., 
1999; Wang et al., 2000). Treatment of SCD consists of daily high doses of orally 
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administered carnitine (100 to 200 mg/kg body weight), to ensure its absorption and 
to reverse or attenuate the clinical symptoms, whereas carnitine concentrations 
increase slightly in skeletal muscle and reach nearly normal levels in the liver, but 
without restoring totally the tissues carnitine stores (Angelini et al., 1992). 
 
II. Myopathic Carnitine Deficiency (MCD) 
 
In muscle carnitine deficiency, lipid storage myopathy occurs with low muscle 
carnitine but normal liver and serum carnitine and affected patients suffer from 
progressive muscle weakness and some of them from lipid storage myopathy (Engel 
and Angelini, 1973; Markesbery et al., 1974; VanDyke et al., 1975). Due to normal 
plasma levels, it has been assumed that MCD is associated with a defect in the low 
affinity muscle-specific carnitine transporter (Martinuzzi et al., 1991), and that this 
form of carnitine deficiency can be inherited as an autosomal recessive disorder, 
since parents also had low muscle carnitine levels (VanDyke et al., 1975). Carnitine 
treatment has been beneficial on muscle strength in some patients only, whereas the 
muscle carnitine content was increased with variable success, but carnitine stores 
were only rarely replenished (Hosking et al., 1977; Shapira et al., 1993). However, in 
order to achieve full recovery the duration of therapy should probably continue for 
longer periods, with a dose of not less than 100 mg/kg body weight/day (Shapira et 
al., 1993). 
 
 
5.1.6.2 Secondary carnitine deficiency 
 
Secondary carnitine deficiency, manifested by decreased plasma or tissue carnitine 
levels, is associated primarily with a wide range of genetic diseases, caused by 
metabolic disorders (Pons and De Vivo, 1995). These disorders are associated with 
impaired oxidation and accumulation of atypical acyl-CoA intermediates, and include 
fatty acid oxidation disorders and amino acid oxidation defects, and are characterized 
by plasma and tissue carnitine levels of 25 to 50% of normal (Stanley, 1987). Fatty 
acid oxidation defects, inherited in an autosomal recessive manner, can be 
subdivided into defects of the carnitine cycle for the transport of the long-chain fatty 
acids into mitochondria and defects of the β-oxidation cycle, that occur within the 
 - 26 - 
mitochondria (Pons and De Vivo, 1995). Defects of the enzymes involved in the 
carnitine cycle implicates carnitine-acylcarnitine translocase deficiency (Stanley et al., 
1992) and carnitine palmitoyltransferase I and II deficiencies (Angelini et al., 1981). 
Defeciences due to the enzymes involved in the β-oxidation cycle comprise the short-
chain (Turnbull et al., 1984), the medium-chain (Roe et al., 1986), the long-chain 
(Hale et al., 1985) and the very long-chain acyl-CoA dehydrogenases (Bertrand et al., 
1993). The postulated mechanism of carnitine deficiency in these disorders is an 
imbalance between the urinary excretion of the accumulated acylcarnitines and the 
sum of the dietary intake and biosynthesis of carnitine, resulting in the accumulation 
of the corresponding acyl-CoA esters in mitochondrial matrix and a characteristic 
increase of the acylcarnitine to carnitine ratio (Chalmers et al., 1984; Rebouche and 
Paulson, 1986). 
 
Several drugs such as the branched fatty acid valproic acid (VPA), pivalic acid 
containing pro-drugs, cisplatin or carnitine derivates are involved in secondary 
carnitine deficiency (Opala et al., 1991; Holme et al., 1992; Heuberger et al., 1998; 
Brass et al., 2003). It has been shown that these drugs have inhibitory effect on 
OCTN2-mediated carnitine transport, whereas the most potent blockers were the 
antibiotic emetine and the ion channel blockers quinidine and verapamil (Ohashi et 
al., 1999; Wu et al., 1999; Wagner et al., 2000; Wu et al., 2000). Since no significant 
inhibition of carnitine transport by VPA was found, it was suggested that the 
deficiency induced by valproate therapy is due to a different mode of action. 
 
 
5.1.7 Juvenile Visceral Steatosis (jvs) Mouse 
 
In 1988, Koizumi et al. (Koizumi et al., 1988) described a C3H-H-2° strain of mouse, 
autosomal recessively associated with microvesicular fatty infiltration of viscera. The 
mice, later renamed juvenile visceral steatosis (jvs) mice (Hayakawa, 1990), show, 
beside severe lipid accumulation in the liver, other features of carnitine deficiency 
such as hyperammonemia, hypoglycemia, cardiac hypertrophy, mitochondrial 
abnormalities in skeletal muscle and progressive growth retardation (Horiuchi et al., 
1993; Kaido et al., 1997). The hyperammonemia in jvs mice has been described as a 
consequence of a decrease of all the urea cycle enzyme activities resulting from 
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suppressed transcription during development (Imamura et al., 1990; Tomomura et 
al., 1992; Tomomura et al., 1994).  They also have cardiac hypertrophy that can be 
significantly suppressed after carnitine administration (Horiuchi et al., 1993), and they 
were shown to have a marked decrease of carnitine levels in serum, liver and 
muscle, in comparison with controls (Kuwajima et al., 1991). After carnitine treatment, 
all the symptoms disappear, and carnitine substitution corrects carnitine deficiency 
and also reduces cardiac hypertrophy and hepatic accumulation of fat (Horiuchi et al., 
1992). The jvs mice are therefore established as a model for SCD since they also 
show symptoms similar to those observed in SCD patients (Koizumi et al., 1988). 
 
The metabolic defect in jvs mice was suspected to be primarily due to impairment of 
the renal carnitine transport system, and studies on the renal reabsorptional capacity 
of carnitine in the jvs mice revealed that the affected homozygous mice showed a 
higher rate of carnitine excretion ten days after birth (Horiuchi et al., 1994; Horiuchi et 
al., 1997). Biochemical studies of carnitine transport, using cultured fibroblast from 
normal and mutant jvs mice, indicated that the mutant jvs had significantly lower rates 
of Na+-dependent carnitine uptake than controls (Kuwajima et al., 1996). The jvs 
phenotype is inherited in an autosomal recessive manner (Hayakawa, 1990) and the 
jvs locus has been identified within a 1.6 cM region on mouse chromosome 11 
(Nikaido et al., 1995; Okita et al., 1996). The missense mutation in the jvs mouse was 
identified as L352R and is characterized on the molecular level by a point mutation 
from CTG to CGG that substituted from leucine to arginine at amino acid position 352 
in the mouse homologue of OCTN2 (Lu et al., 1998). All these findings indicate that 
jvs mice represent a valid animal model for human primary carnitine deficiency. 
 
 
5.1.8 Valproic Acid (VPA) 
 
Valproic acid (N-dipropylacetic acid) or valproate (VPA) is a branched, medium-chain 
fatty acid composed of eight carbons (Figure 7), which is structurally unrelated to 
other antiepileptic drugs. VPA is a broad-spectrum antiepileptic drug which was 
introduced into the anticonvulsant market in 1968 in Europe and in 1978 in the United 
States (Zafrani and Berthelot, 1982). It is routinely used for both partial and 
generalized seizures, and it is effective against abscences (typical petit mal) 
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seizures, atypical absence seizures, myoclonic and tonic-clonic (grand mal) seizures 
and can be used as second choice medication in status epilepticus (Koch-Weser and 
Browne, 1980). The most common side effects are gastrointestinal disturbances 
(anorexia, nausea, vomiting), sedation, coagulation disorders (thrombocytopenia, 
decreased serum fibrinogen, prolonged prothrombin time), alopecia and hepatic 
toxicity (Pinder et al., 1977; Bruni and Wilder, 1979; Koch-Weser and Browne, 1980). 
Shortly after introduction, cases of fulminant liver failure in patients treated with VPA 
have been reported (Zafrani and Berthelot, 1982; Zimmerman and Ishak, 1982; 
Dreifuss et al., 1987; Konig et al., 1994; Krahenbuhl et al., 1995), but the underlying 
mechanism of VPA induced hepatotoxicity is still not fully known. 
 
 
 
 
 
 
 
Figure 7: Valproic Acid 
 
 
 
5.1.8.1 Pharmacology of VPA 
 
VPA potentiates γ-aminobutyric acid (GABA) ergic inhibitory effects in some specific 
brain regions that are involved in the control of seizure generation and propagation 
by increasing both GABA synthesis and release (Bolanos and Medina, 1997; 
Loscher, 2002). Additionally, VPA also interacts with the metabolism of γ-
hydroxbutyrate (GHB), a metabolite of GABA, reducing the GHB release and 
attenuating the neuronal excitation induced by N-methyl-D-aspartate type glutamate 
receptors (Loscher, 2002).   
Therapeutic serum concentrations range from 50 to 125 µg/ml. At such therapeutic 
concentrations VPA is 80 to 90% bound to serum proteins. The binding is 
concentration-dependent, whereas the percentage decreases at higher VPA levels 
(Gugler and von Unruh, 1980; Chadwick, 1985). The protein bound fraction is less in 
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patients with renal disease, chronic hepatic disease, in the elderly, during pregnancy 
and in the presence of other protein bound drugs  (Klotz and Antonin, 1977; Davis et 
al., 1994).  
The metabolism of VPA follows at least five main metabolic pathways in the liver 
including glucuronidation, mitochondrial β-oxidation and cytosolic ω-oxidation 
(catalyzed by microsomal cytochrome P450) to produce multiple metabolites (Figure 
8). However, because of their low plasma and brain concentrations, it is unlikely that 
they contribute significantly to the anticonvulsant effects of VPA (Davis et al., 1994; 
Loscher, 2002). Nevertheless, some of them may be involved in toxic effects of VPA, 
whereas the exact mechanism is not fully elucidated.  
 
 
 
Figure 8: Liver metabolism and metabolites of VPA 
 
 
Mitochondrial β-oxidation of VPA involves its transport within the mitochondrial matrix 
using the same pathway as long-chain fatty acids. This pathway consists of several 
steps and is called the “carnitine shuttle” (Figure 9). First, VPA is activated in the 
cytosol and links with coenzyme A (CoA-SH) to form valproyl-CoA. Valproyl-CoA 
then crosses the outer mitochondrial membrane. Under the effect of carnitine 
palmitoyltransferase I, valproylcarnitine is formed. Valproylcarnitine is then 
exchanged for free carnitine by carnitine-acylcarnitine translocase. In the 
mitochondrial matrix, carnitine palmitoyltransferase II transforms valproylcarnitine into 
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valproyl-CoA, which is able to enter a β-oxidation process (Millington et al., 1985; Li 
et al., 1991; Ketter et al., 1999). 
 
 
 
Figure 9: The ‘carnitine shuttle’. ACoAs, acyl-CoA synthetase; CoA, coenzyme A; CPT, carnitine 
palymitoyltransferase; CT, carnitine translocase 
 
 
 
5.1.8.2 VPA-associated hepatotoxicity 
 
The hepatotoxicity associated with VPA has been well documented (Sussman and 
McLain, 1979; Dickinson et al., 1985; Eadie et al., 1988). The type I VPA-mediated 
hepatotoxicity is associated with dose-dependent changes in serum aminotrans-
ferase activity and low plasma fibrinogen levels that are normalized with either dose 
reduction or drug discontinuation. This dose-related toxicity occurs during the first 
three months of therapy in up to 44% of recipients (Sussman and McLain, 1979; 
Coulter et al., 1980). The type II VPA-mediated hepatotoxicity is considered to be 
rare, but often fatal and irreversible idiosyncratic reactions characterized by centri- 
and midzonal microvesicular steatosis that is sometimes accompanied by centrizonal 
necrosis (Zafrani and Berthelot, 1982; Zimmerman and Ishak, 1982; Dreifuss et al., 
1987). This severe form of hepatotoxicity is not clearly dose-dependent, as it can 
arise with either low doses (or low VPA plasma concentrations) or high doses (or 
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high VPA plasma concentrations) (Zimmerman and Ishak, 1982; Dreifuss et al., 
1987). 
 
Although the mechanism of the type II VPA-mediated hepatotoxicity is not fully 
elucidated, mitochondrial dysfunction was considered as principal cause of VPA-
induced liver failure (Fromenty and Pessayre, 1995). In agreement with this concept, 
microvesicular steatosis, the principal histological finding in valproate induced 
hepatotoxicity, is also detected in other types of liver disease with decreased 
mitochondrial β-oxidation such as Reye’s syndrome, Jamaican vomiting sickness, 
mitochondrial cytopathies and acute fatty liver of pregnancy (Bioulac-Sage et al., 
1993; Ponchaut and Veitch, 1993). 
Since VPA is activated to both CoA and carnitine derivates, depletion of hepatic free 
CoA and free carnitine represents a potential mechanism, whereas this sequestration 
of CoA and carnitine is thought to be the major cause for the inhibition of 
mitochondrial β-oxidation by VPA (Ponchaut et al., 1992b). Another mechanism may 
be direct inhibition of mitochondrial β-oxidation by VPA metabolites, namely 4-ene 
VPA (∆4-VPA) and its subsequent metabolite 2,4-diene VPA, resulting in an 
inactivation of mitochondrial β-oxidation enzymes (Thurston et al., 1983; Turnbull et 
al., 1983; Granneman et al., 1984; Rettenmeier et al., 1985; Ponchaut et al., 1992b). 
A third possible mechanism is a decreased activity of complex IV (cytochrome c 
oxidase) of the respiratory chain, associated with a significant loss in cytochrome aa3 
in liver mitochondria (Ponchaut et al., 1991a; Ponchaut et al., 1991b; Ponchaut and 
Veitch, 1993). Furthermore, it has been proposed that pre-existing mitochondrial 
diseases, e.g. impaired β-oxidation and/or impaired function of the respiratory chain, 
may increase susceptibility for VPA-induced mitochondrial dysfunction, in particular 
for liver failure (Chabrol et al., 1994; Lam et al., 1997; Krahenbuhl et al., 2000a). 
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5.2 In vitro investigations 
 
5.2.1 Immortalized human hepatocytes 
 
Primary human hepatocytes are widely used for xenobiotic metabolism, toxicity 
studies and the design for bioartificial liver devices. Nevertheless, there are several 
disadvantages occurring with this screening system. Primary hepatocytes have 
limited and unpredictable availability, restricted growth activity and lifespan, and show 
significant inter-individual differences in the expression of drug metabolizing enzymes 
and responses to toxicants. Huge variations in functional activities, especially P450 
levels, as well as in the magnitude of P450 induction after treatment with prototypical 
inducers, have been reported from one human hepatocyte population to another 
(Guillouzo et al., 1993; Madan et al., 2003). 
 
In contrast to primary human hepatocytes, immortalized hepatocytes could be taken 
into consideration for investigations on hepatic metabolism or drug toxicity. These 
cells are readily available, can be passaged and used over a longer time period, 
retaining the activity of major drug-metabolizing enzymes. On a cellular basis, 
mortality is defined as the death of a lineage of cells, immortality would be defined as 
infinite survival, a life span without time limits, unlimited proliferative potential and 
maintenance of critical liver functions (Cascio, 2001). The most widely used 
immortalizing agent that allow normal cells to overcome senescence signals and 
continue proliferating, is the simian virus 40 large T antigen (SV40TAg). The common 
mode of action of this viral oncogene is the inactivation of the cell cycle regulatory 
proteins pRB and p53 by various mechanisms (Bryan and Reddel, 1994; Mathon and 
Lloyd, 2001).  
 
The development of an immortalized hepatocyte cell line would be beneficial for the 
pharmaceutical industry and an enormous need exists for an in vitro human 
hepatocyte assay system for high throughput testing of the pharmacological 
properties and toxicology of new chemical entities (NCE). A differentiated human 
hepatocyte cell line, especially one which exhibits P450 function, would find 
immediate and widespread application in pharmacology and toxicology. The used 
immortalized human hepatocyte cell line was generated in our laboratory by 
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transducing the SV40TAg gene into primary human hepatocytes, using a HIV-derived 
lentiviral vector as described by Salmon et al. (Salmon et al., 2000). 
 
 
5.2.2 Hepatic cell lines 
 
A frequently used alternative for the screening of hepatic metabolism and toxicity of 
several drugs is the utilization of hepatic cell lines, deriving from hepatoblastoma or 
hepatocellular carcinoma. 
 
5.2.2.1 HepG2 
 
The hepatocellular carcinoma HepG2 cell line is a perpetual adherent cell line which 
has been isolated primarily from a liver tissue of a 15 year old Caucasian male with a 
well differentiated hepatocellular carcinoma. These cells are epithelial in morphology 
and have a model chromosome number of 55. The cells secrete a variety of major 
plasma proteins, e.g. albumin, α-2 macroglobulin, α-1 antitrypsin, transferrin and 
plasminogen, and have provided a tool for extensive studies of biochemical functions 
of liver cells and used to test a wide variety of compounds over the last years (Bouma 
et al., 1989; Javitt, 1990). In our studies this cell line was used as a comparator to 
investigate the expression and induction of several CYP isozymes and the human 
pregnane X receptor (hPXR).  
 
 
5.2.3 Cytochrome P450 enzymes  
Cytochome P450s (CYPs) are a large group of heme-containing monooxygenase 
enzymes responsible for the oxidative metabolism of drugs and other xenobiotics, as 
well as many endogenous compounds, whereas NADPH is required as a coenzyme 
and O2 is used as a  substrate. They are classified in the same family (symbolized by 
an Arabic number) when their amino acid sequence similarity is greater than 40% 
and to the same subfamily (symbolized by an upper case letter) when their amino 
acid sequence similarity is above 55% (Nebert et al., 1987; Nebert and Gonzalez, 
1987). CYPs are located on the membrane of the endoplasmic reticulum and are 
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highly concentrated in the liver and in the small intestine, and they are also found in 
the mitochondrial membrane (Modi et al., 1995). Presently, there are more than 270 
different CYP gene families, with 18 recommended in mammals (Nebert and Russell, 
2002) (Figure 10). Up to now, three main P450 families (1, 2 and 3) have been 
identified as mainly involved in xenobiotic metabolism (Gonzalez, 1988; Nelson et al., 
1993), and drug-drug interacations (DDI) are of increasing interest due to the 
occurrence of adverse drug reactions and/or loss of therapeutic effect (Li et al., 
1997b; Michalets, 1998; Madan et al., 2003). Induction of CYP3A4 gene expression 
is caused by a variety of marketed drugs, including rifampin, phenobarbital, 
clotrimazole and dexamethasone (Meunier et al., 2000; Sahi et al., 2000; Luo et al., 
2002; Madan et al., 2003) and represents the basis for a number of common drug-
drug interactions. CYP1A2 is inducible by 3-methylcholanthrene, β-naphtofavone and 
tetrachlorodibenzodoxin (Li et al., 1998; Breinholt et al., 1999; Meunier et al., 2000; 
Madan et al., 2003). CYP2C9 can be induced by rifampin and phenobarbital, 
whereas the magnitude of induction is less than that for CYP3A4 (Li et al., 1997b; 
Madan et al., 2003). Knowledge of possible CYP-induction or -inhibition potential of 
drug candidates in drug discovery or the early preclinical phase of development 
would be therefore helpful for the prediction of drug-drug interactions. Beside 
involvement in drug metabolism, CYPs also play a major part in cholesterol 
biosynthesis and metabolism, bile-acid biosynthesis, steroid synthesis and 
metabolism, vitamin D3 synthesis and metabolism, and retinoic acid hydroxylation 
(Nebert and Russell, 2002). 
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Figure 10: Substrates and functions of human CYP gene families. 
 
 
 
5.2.3.1 CYP1A enzymes 
Members of the CYP1A (CYP1A1 and CYP1A2) subfamily have been identified in a 
wide range of vertebrates, including fish, amphibians, birds, and mammals, and are 
involved in the oxidation of a wide range of endogenous compounds and xenobiotics. 
The expression of members of the CYP1A family is inducible by polycyclic aromatic 
hydrocarbons, such as those found in charbroiled foods and cigarette smoke acting 
through the aryl hydrocarbon receptor (AHR), a transcription factor (Hahn and 
Stegeman, 1994). CYP1A2 is responsible for about 10 to 15% of the total CYP 
content of human liver and is the major CYP isozyme involved in the metabolism of 
important drugs, e.g. imipramine, propranolol, clozapine, olanzapine, theophylline 
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and caffeine (Brosen, 1995). Figure 11 shows the substrates, inhibitors and inducers 
of CYP1A2. 
Substrates, Inhibitors and Inducers of CYP1A2 
 
Substrates  
Amitriptyline (Elavil)  
Clomipramine (Anafranil)  
Clozapine (Clozaril) 
Imipramine (Tofranil)  
Propranolol (Inderal) 
R-warfarin 
Theophylline  
Tacrine (Cognex)  
 
Inhibitors  
Fluvoxamine (Luvox)  
Grapefruit juice  
Quinolones  
Ciprofloxacin (Cipro)  
Enoxacin (Penetrex) > norfloxacin (Noroxin) >  
ofloxacin (Floxin) > lomefloxacin (Maxaquin) 
 
Inducers  
Omeprazole (Prilosec)  
Phenobarbital  
Phenytoin (Dilantin)  
Rifampin (Rifadin, Rimactane)  
Smoking  
Charcoal-broiled meat 
 
Figure 11: Substrates, inhibitors and inducers of CYP1A2. 
 
5.2.3.2 CYP2C enzymes 
 
The CYP2C subfamily is also important for drug metabolism, accounting for 
approximately 18% of the CYP protein content in human liver and for approximately 
20% of the CYP-mediated metabolism of drugs (Rendic and Di Carlo, 1997). 
CYP2C9 is a member of the CYP2C subfamily, which includes in humans at least 
three other members, e.g. CYP2C8, CYP2C18 and CYP2C19. The CYP2C9 isozyme 
is, among others, responsible for the metabolism of several substrates including 
warfarin, phenytoin and various non-steroidal anti-inflammatory agents (Rettie et al., 
1992; Bajpai et al., 1996; Hamman et al., 1997; Miners and Birkett, 1998). CYP2C19 
has been shown to exhibit genetic polymorphism, and is completely absent in 3 
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percent of Caucasians and 20 percent of Japanese (Wedlund et al., 1984; Nakamura 
et al., 1985). It plays a role in the metabolism of phenytoin (Levy, 1995), and is 
involved in the metabolism of omeprazole and diazepam (Andersson et al., 1993; 
Jung et al., 1997) (Figure 12). 
 
 
Substrates, Inhibitors and 
Inducers of CYP2C9 
 
Substrates  
Nonsteroidal anti-inflammatory drugs  
Phenytoin (Dilantin)  
S-warfarin  
Torsemide (Demadex) 
Inhibitors  
Fluconazole (Diflucan)  
Ketoconazole (Nizoral)  
Metronidazole (Flagyl)  
Itraconazole (Sporanox)  
Ritonavir (Norvir) 
Inducers  
Rifampin (Rifadin, Rimactane) 
 
 
 
 
Substrates and Inhibitors of 
CYP2C19 
 
Substrates  
Clomipramine (Anafranil) 
Diazepam (Valium)  
Imipramine (Tofranil)  
Omeprazole (Prilosec)  
Propranolol (Inderal) 
Inhibitors  
Fluoxetine (Prozac)  
Sertraline (Zoloft)  
Omeprazole  
Ritonavir (Norvir) 
 
 
 
 
 
Figure 12: Substrates, inhibitors and inducers of CYP2C9, and substrates and inhibitors of CYP2C19. 
5.2.3.3 CYP2D6 enzyme 
 
CYP2D6, the only known functional member of the CYP2D subfamily in humans, 
metabolizes a wide variety of substances including many psychotherapeutic agents 
(e.g. amitriptyline, haloperidol, risperidone) and also beta-blockers (e.g. metoprolol). 
This enzyme is genetically polymorphic, leading to impaired metabolism in 5 to 10% 
of Caucasians of many centrally acting drugs and toxins (Steiner et al., 1988; Meyer 
et al., 1990). Individuals with normal CYP2D6 activity are termed extensive 
metabolizers. These ultra-rapid metabolizers show increased metabolism and 
decreased drug effects of CYP2D6 substrates, such as tricyclic antidepressants 
(Dalen et al., 1998). Ethnic differences are indicated in this genetic polymorphism, 
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since Asians and blacks are less likely than Caucasians to be poor metabolizers 
(Relling et al., 1991; Bertilsson et al., 1992). Poor metabolizers are at risk for drug 
accumulation and toxicity from drugs metabolized by this isoform. Conversely, when 
formation of an active metabolite is essential for drug action, poor metabolizers of 
CYP2D6 can exhibit less response to drug therapy compared with extensive 
metabolizers. The substrates and inhibitors of CYP2D6 are shown in Figure 13. 
 
Substrates and inhibitors of CYP2D6 
 
Substrates  
Antidepressants* 
Amitriptyline (Elavil)  
Clomipramine (Anafranil)  
Desipramine (Norpramin)  
Doxepin (Adapin, Sinequan)  
Fluoxetine (Prozac)  
Imipramine (Tofranil)  
Nortriptyline (Pamelor)  
Paroxetine (Paxil)  
Venlafaxine (Effexor)  
 
Antipsychotics  
Haloperidol (Haldol)  
Perphenazine (Etrafon, Trilafon)  
Risperidone (Risperdal)  
Thioridazine (Mellaril) 
  
Beta blockers  
Metoprolol (Lopressor)  
Penbutolol (Levatol)  
Propranolol (Inderal) 
Timolol (Blocadren)  
Narcotics  
Codeine, tramadol (Ultram)  
Inhibitors  
Antidepressants  
Paroxetine > fluoxetine >  
sertraline (Zoloft) > fluvoxamine  
(Luvox),  
Nefazodone (Serzone),  
Venlafaxine > clomipramine  
(Anafranil) > amitriptyline  
Cimetidine (Tagamet)  
Fluphenazine (Prolixin)  
Antipsychotics  
Haloperidol  
Perphenazine  
Thioridazine  
 
Figure 13: Substrates and inhibitors of CYP2D6. 
5.2.3.4 CYP3A enzymes 
CYP3A enzymes are the most abundantly expressed cytochrome P450 enzymes in 
the liver and is considered to be the major drug metabolizing subfamily. Its members 
are localized in the organs most associated with drug disposition, including the liver, 
gastrointestinal tract, and kidney. CYP3A4 is the predominant cytochrome P450 
enzyme, accounting for up to 30% of total hepatic CYP protein content (Shimada et 
al., 1994), and is known to metabolize a large variety of xenobiotics (among them 
amiodarone, lipophilic HMG-CoA reductase inhibitors, cyclosporine, tacrolimus and 
sirolimus, and various anticancer drugs) and endogenous substances, such as 
steroids (Brian et al., 1990; Araya and Wikvall, 1999). Other isoforms are CYP3A43, 
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CYP3A5 and CYP3A7. Among them, it has been estimated that about 60% of all 
clinically used drugs are metabolized by CYP3A4 (Bertz and Granneman, 1997). 
Members of this subfamily are involved in many clinically important drug interactions 
(Slaughter and Edwards, 1995). Several potent inducers of CYP3A are known, 
including rifampicin, dexamethasone and phenorbarbital (Meunier et al., 2000; Sahi 
et al., 2000; Luo et al., 2002; Madan et al., 2003), leading to clinically important drug-
drug interactions when these substances are administered concurrently with drugs, 
which are metabolized by these CYPs. Substrates, inhibitors and inducers of CYP3A 
are listed in Figure 14. 
CYP3A43 gene expression was found in liver, kidney, pancreas, and prostate as well 
as fetal liver and fetal skeletal muscle (Domanski et al., 2001). The highest 
expression level of CYP3A43 mRNA was found in prostate, and in liver it could be 
induced by rifampicin (Gellner et al., 2001). CYP3A43 is expressed at 0.1% and 2% 
of the levels of CYP3A4 and CYP3A5 (Westlind et al., 2001).  
CYP3A5 was isolated from a liver cDNA library and was first termed PCN3, sharing 
85% sequence similarity with CYP3A4 (Aoyama et al., 1989). It is present at only 10 
to 30% of CYP3A4 levels (Kuehl et al., 2001). It is well established that only 
approximately 20% of livers express CYP3A5. The most common reason for the 
absence of expression is a splice site mutation (Kuehl et al., 2001; Lin et al., 2002). 
In individuals who express CYP3A5, the percentage contributed to total hepatic 
CYP3A by this isoform is still unclear, with estimates ranging from 17% to 50%, 
wheras CYP3A5 was more frequently expressed in livers of African Americans (60%) 
than in those of Caucasians (33%) (Kuehl et al., 2001). CYP3A5 is also expressed in 
a range of extrahepatic tissues such as small intestine, colon esophagus and lung 
(Ding and Kaminsky, 2003).  
CYP3A7 is expressed specifically in fetal livers and accounts for up to 50% of the 
total fetal hepatic CYP content (Wrighton and Vandenbranden, 1989). It has been 
shown that CYP3A7 is expressed in placental and endometrial microsomes that 
increases dramatically from the first to the second trimester of pregnancy. An 
increased expression of a CYP3A7 transcript was found in endometria of pregnant 
compared with nonpregnant women as well as an increase from the first to the 
second trimester of pregnancy (Schuetz et al., 1993). The level of expression of 
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CYP3A7 varies with gestational age and is higher in the 20-week fetus than at 40 
weeks of age, and decreases dramatically after birth (Kitada et al., 1987). Initially, 
CYP3A7 was thought to be unique to the fetal liver (Wrighton and Vandenbranden, 
1989), however, its presence has now been noted in placental, endometrial (Schuetz 
et al., 1993), and adult hepatic tissue (Schuetz et al., 1994). 
Substrates, Inhibitors and Inducers of CYP3A 
 
Substrates  
Amitriptyline (Elavil)  
Benzodiazepines  
Alprazolam (Xanax)  
Triazolam (Halcion)  
Midazolam (Versed)  
Calcium blockers  
Carbamazepine (Tegretol)  
Cisapride (Propulsid)  
Dexamethasone (Decadron)  
Erythromycin  
Ethinyl estradiol (Estraderm, Estrace)  
Glyburide (Glynase, Micronase)  
Imipramine* (Tofranil)  
Ketoconazole (Nizoral)  
Lovastatin (Mevacor)  
Nefazodone (Serzone)  
Terfenadine (Seldane)  
Astemizole (Hismanal)  
Verapamil (Calan, Isoptin)  
Sertraline (Zoloft)  
Testosterone  
Theophylline  
Venlafaxine (Effexor)  
Protease inhibitors  
Ritonavir (Norvir)  
Saquinavir (Invirase)  
Indinavir (Crixivan)  
Nelfinavir (Viracept)  
Inhibitors  
Antidepressants  
Nefazodone > fluvoxamine (Luvox) > fluoxetine  
(Prozac) > sertraline  
Paroxetine (Paxil)  
Venlafaxine  
Azole antifungals  
Ketoconazole (Nizoral) > itraconazole (Sporanox)  
> fluconazole (Diflucan)  
Cimetidine (Tagamet) 
Clarithromycin (Biaxin)  
Diltiazem  
Erythromycin  
Protease inhibitors  
Inducers  
Carbamazepine  
Dexamethasone  
Phenobarbital  
Phenytoin (Dilantin)  
Rifampin (Rifadin, Rimactane)  
 
Figure 14: Substrates, inhibitors and inducers of CYP3A4. 
5.2.4 Human pregnane X receptor (PXR) 
 
The pregnane X receptor (PXR), an orphan nuclear receptor, is one of the key 
transcriptional regulators of cytochrome P450 CYP3A monooxygenases and other 
drug metabolizing enzymes and transporters, such as CYP2B6, CYP2C8/9 and 
CYP3A7, as well as the drug transporters MDR1, OATPC, bile salt export pump 
(BSEP) and MRP2 (Schuetz et al., 2001; Kast et al., 2002; Pascussi et al., 2003; 
Tirona et al., 2003). PXR is a member of the nuclear receptor family of ligand-
activated transcription factors that includes the steroid, retinoid, and thyroid hormone 
receptors as well as many orphan receptors for which physiological ligands have yet 
to be identified (Mangelsdorf et al., 1995; Giguere, 1999), and is highly expressed in 
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the liver and intestine. The human PXR, that binds to the rifampicin/dexamethason 
response element in the CYP3A4 promoter (Lehmann et al., 1998), is activated by a 
variety of endogenous (e.g. steroids and bile acids), and exogenous compounds (e.g. 
rifampicin, phenytoin and hyperforin) through direct interaction with these ligands. 
After activation by the ligand, PXR forms heterodimers with the 9-cis retinoic X 
receptor (RXR), another nuclear receptor. The emerging heterodimer binds to 
specific DNA sequences and regulates the expression of its targets. The elucidation 
of the three-dimensional structure of the PXR ligand binding domain has provided 
important insights into the structural basis for the promiscuous ligand binding 
properties of this nuclear receptor (Watkins et al., 2001). PXR activation assays can 
be used to predict the induction of CYP3A gene expression by drug candidates and 
therefore to predict drug-drug interactions (Lehmann et al., 1998; Goodwin et al., 
2002; Kliewer et al., 2002).  
 
5.2.5 Cimicifuga racemosa (Black cohosh) 
 
 
 
Figure 15: Cimicifuga racemosa – plant and rhizome. 
 
 
Cimicifuga racemosa (Actaea racemosa) (Figure 15), commonly known as black 
cohosh, is an herb native to Eastern North America. Traditionally, the root and 
rhizome was used by North American Indians for joint aches, myalgias, neuralgias 
and rheumatic disorders, but also for menopausal complaints and pain during labour. 
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Nowadays, ethanolic or isopropanolic extracts of cimicifuga racemosa are most 
commonly used in the treatment of menopausal symptoms, menstrual dysfunction 
and other gynaecological disorders, although not all studies have shown a better 
effect than placebo (McKenna et al., 2001; Frei-Kleiner et al., 2005; Nappi et al., 
2005; Pockaj et al., 2006; Uebelhack et al., 2006). 
The therapeutic activity of black cohosh was originally suggested to derive from an 
activation of estrogen receptors (Jarry et al., 1985; Duker et al., 1991; Kruse et al., 
1999; Liu et al., 2001b), however, in other studies, estrogenic or estrogen receptor-
binding effects were not found (Einer-Jensen et al., 1996; Liu et al., 2001a). Since it 
is unclear if black cohosh has an estrogenic effect or not and due to its potential 
ability to stimulate uterine contraction, it is contraindicated during pregnancy (Mahady 
et al., 2002).  
Data from clinical studies and spontaneous reporting programs suggest that adverse 
events associated with cimicifuga racemosa are rare, generally mild and reversible. 
Gastrointestinal upset and rashes were the most common adverse events reported 
(Dog et al., 2003; Huntley and Ernst, 2003). In mostly uncontrolled clinical trials and 
post-marketing studies including more than 2,800 patients, adverse events had an 
incidence of 5.4%. Of the reported adverse events, 97% were minor or mild, none of 
them resulting in discontinuation of the therapy. When higher doses than those 
recommended are used, however, cimicifuga racemosa can cause dizziness, 
headaches, nausea, and vomiting (Dog et al., 2003). In their review, which includes 
all post-marketing programs of cimicifuga extracts, Huntley et al. also described 
patients with hepatic adverse events (Huntley and Ernst, 2003). They reported one 
case with hepatic failure, three cases with hepatitis and three cases with increased 
liver enzymes. In addition, several case reports have been published about patients 
developing acute hepatitis (Whiting et al., 2002; Cohen et al., 2004) or fulminant liver 
failure (Lontos et al., 2003; Levitsky et al., 2005; Lynch et al., 2006) while being 
treated with cimicifuga extracts. Since an association of hepatotoxicity with cimicifuga 
appears to be possible and there are only limited data available, it is of great interest 
to further investigate the toxicological profile and the factors contributing to the 
potential toxicity of black cohosh. 
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6.1 Abstract 
 
Aims: To study carnitine homeostasis and energy metabolism in carnitine-deficient 
(jvs-/-) mice after cessation of carnitine substitution. 
Methods: Homozygous jvs-/- mice starved overnight were studied 3, 6 and 10 days 
after cessation of carnitine substitution and compared to wild-type and heterozygous 
jvs+/- mice. 
Results: In comparison to wild type mice, jvs-/- mice treated with oral carnitine had a 
higher liver weight and hepatic fat accumulation, and decreased plasma β-
hydroxybutyrate levels. The total carnitine concentrations in plasma, liver and skeletal 
muscle were decreased by 58%, 16% and 17%, respectively. After cessation of 
carnitine administration, the plasma carnitine levels fell rapidly, reaching 2.3 µmol/L 
after 10 days. After 10 days of carnitine deprivation, the hepatic and skeletal muscle 
carnitine content had dropped to 51% and 66%, respectively, of carnitine-treated jvs-
/- mice. Carnitine deprivation was associated with a further drop in the plasma β-
hydroxybutyrate levels and hepatic fat accumulation. In skeletal muscle, the glycogen 
content decreased and the lactate levels increased with carnitine deprivation, 
whereas tissue ATP levels were maintained. 
Conclusions: Although the tissue stores of carnitine are quite resistant to carnitine 
deprivation in mice with systemic carnitine deficiency, the margin between adequate 
function and failure of energy metabolism is narrow. 
 
Key words: jvs-/- mice, systemic carnitine deficiency, β-oxidation, glycogen, ATP 
Abbreviations: JVS, juvenile visceral steatosis; OCTN2, organic cation / carnitine 
transporter; SCD, systemic carnitine deficiency 
 
6.2 Introduction 
 
Carnitine (β-hydroxy-4-N-trimethylaminobutyric acid) represents an essential cofactor 
for the transport of activated long-chain fatty acids across the inner mitochondrial 
membrane to the mitochondrial matrix, the place of β-oxidation (Bremer, 1983; 
Rebouche and Paulson, 1986). Since fatty acids are an important energy source for 
many organs, carnitine deficiency is associated with cardiomyopathy, muscle 
weakness, encephalopathy and/or hepatopathy including Reye’s syndrome (Karpati 
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et al., 1975; Chapoy et al., 1980; Treem et al., 1988). Carnitine is a polar molecule 
with a high intracellular concentration, necessitating an active transport from the 
plasma into cells. OCTN2 is a carnitine transporter, which has been characterized 
intensively on both the molecular and on the functional level (Tamai et al., 1998). The 
functional importance of OCTN2 is evidenced in patients with mutations in the 
corresponding gene, leading to primary systemic carnitine deficiency due to a lack of 
renal carnitine reabsorption (Nezu et al., 1999; Seth et al., 1999; Vaz et al., 1999; 
Wang et al., 1999). Primary systemic carnitine deficiency (SCD; OMIM 212140) is an 
autosomal recessive disorder of fatty acid oxidation, clinically characterized by 
progressive cardiomyopathy, skeletal myophathy, hypoglycemia and 
hyperammonemia (Karpati et al., 1975; Treem et al., 1988). C3H.OH (formerly C3H-
H-2°) mice, which are characterized by microvesicul ar steatosis of the liver and 
triglyceride accumulation in other visceral organs, were first described 1988 by 
Koizumi et al. (Koizumi et al., 1988) and were later renamed juvenile visceral 
steatosis (jvs) mice (Hayakawa, 1990). The jvs phenotype is inherited in an 
autosomal manner (Hayakawa, 1990) and is characterized on the molecular level by 
a point mutation in the mouse homologue of OCTN2, leading to an exchange of an 
amino acid (L352R) (Lu et al., 1998). Beside liver steatosis, jvs mice show other 
features of carnitine deficiency such as hyperammonemia, hypoglycemia, cardiac 
hypertrophy, mitochondrial abnormalities in skeletal muscle and progressive growth 
retardation (Horiuchi et al., 1993; Kaido et al., 1997). The accumulation of lipids 
occurs within 5 days of birth whereas hypoglycemia, hyperammonemia and growth 
retardation appear approximately 2 weeks later (Horiuchi et al., 1994). 
Hyperammonemia has been described as a consequence of a decrease in urea cycle 
enzyme activities due to reduced transcription of the corresponding genes (Imamura 
et al., 1990; Tomomura et al., 1992; Tomomura et al., 1994). As expected, as a 
consequence of impaired renal reabsorption of carnitine, plasma and tissue carnitine 
levels are substantially decreased in jvs as compared to wild type mice (Kuwajima et 
al., 1991). Carnitine substitution corrects carnitine deficiency and transcription of the 
urea cycle enzymes at least partially and also reduces cardiac hypertrophy and 
hepatic accumulation of fat (Horiuchi et al., 1992). These findings demonstrate that 
jvs mice represent an excellent animal model for primary systemic carnitine 
deficiency in humans. 
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While it is well established that sufficient carnitine plasma and tissue levels can be 
obtained in jvs mice by carnitine substitution, the kinetics of carnitine loss from 
plasma and tissues after carnitine deprivation and the consequences on energy 
metabolism have not been described so far. We therefore studied plasma and tissue 
carnitine stores and markers of energy metabolism after cessation of carnitine 
substitution in jvs mice. 
 
6.3 Materials and Methods 
 
Animals 
The juvenile visceral steatosis (jvs) mice were obtained from Prof. Masahisa Horiuchi 
from the University of Kagoshima, Japan. The breeding pairs (wild type and 
heterozygous jvs+/-) and the offsprings were supplemented with carnitine (1g/250ml 
drinking water) before weaning to maintain the survival rate. After weaning, the 
supplementation with carnitine was continued for the homozygous jvs-/- mice. For 
genotyping the littermates (wild type, heterozygous jvs+/- and homozygous jvs-/- 
mice), DNA was extracted and purified from a piece of tail using a DNA extraction kit 
(kit No. 740952.250, Macherey-Nagel, Oensingen, Switzerland). A TaqMan allelic 
discrimination method was established which combines PCR and mutation detection 
in a single step. Two allele-specific TaqMan probes were used, one for each allele 
(Applied Biosystems, UK). Each probe consisted of an oligonucleotide with a 5’ 
reporter dye (FAM for the detection of the wild type L352 allele and VIC for the 
detection of the mutant L352R allele) and a 3’ quencher dye (TAMRA for both 
probes). The probes were as follows: FAM, 5’-atatggtcagcctgca-3’ and VIC, 5’-
tatggtccgcctgca-3’. The primers used (Microsynth, Switzerland) were identically for 
both alleles and were designed as follows: forward primer, 5’-tccccatgcaagttaggagtgt-
3’, reversed primer, 5’-tgctgctccagctctcttctg-3’. TaqMan analysis was carried out on a 
7900HT Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland) 
and identification of the mutation in Octn2 was achieved using an allelic 
discrimination plot (Todesco et al., 2003). Cycling conditions were 10 min at 95°C for 
initial denaturation and activation of the DNA polymerase, followed by 40 cycles of 15 
s at 95°C for denaturation and 1 min at 60°C for co mbined annealing and primer 
extension. Fluorescence from the FAM reporter only reflects the presence of wild 
type alleles, whereas fluorescence from the VIC reporter only indicates mutant 
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alleles. Accordingly, fluorescence from both reporters reflects the heterozygous 
population.  
 
Study Design 
All experiments had been reviewed and accepted by the Animal Ethics Committee of 
the State of Basel Stadt. Experiments were performed with animals of 6 to 8 weeks 
old. 
Six groups of jvs mice were studied. Wild type (WT), heterozygous jvs+/- and 
homozygous jvs-/- with carnitine supplementation (n=5 per group) were starved 
overnight before entering the final part of the study. After having obtained a blood 
sample from the tail vein, the mice were killed by decapitation. Tissue samples were 
obtained from the liver and skeletal muscle (quadriceps femoris), frozen rapidly by 
immersion in liquid nitrogen and stored at -70°C un til analysis. These tissue samples 
were analyzed for carnitine and markers of energy metabolism. Frozen liver tissue 
was also used for staining with Sudan Black B (see below). Additional liver and 
skeletal muscle samples were treated with 4% formaldehyde for histological analysis. 
The other 3 groups of animals were homozygous jvs-/- mice deprived from carnitine 
(drinking water without containing carnitine) for 3, 6 or 10 days (n=5 per group). After 
the respective carnitine deprivation period, mice were starved overnight and killed by 
decapitation the next morning. Blood, liver and muscle samples were collected and 
stored as described above. 
 
Characterization of the animals 
The animals were characterized by their body and liver weights, levels of glycogen, 
lactate and ATP in liver and muscle and their plasma concentration of β-
hydroxybutyrate. Lactate, ATP and glycogen were measured spectrophotometrically 
as described by Harris et al. (Harris et al., 1974), after adaptation of the method for a 
SpectraMax 250 absorbance microplate reader (Molecular Devices Corp.). β-
Hydroxybutyrate was determined fluorimetrically according to Olsen (Olsen, 1971), 
after adaptation of the method for a SpectraMax Gemini XS (Molecular Devices 
Corp.) plate reader. 
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Determination of plasma and tissue carnitine 
The carnitine concentrations in plasma, liver and muscle were determined 
radioenzymatically as described by Brass and Hoppel (Brass and Hoppel, 1978). 
Plasma and tissue samples were treated with perchloric acid (final concentration 3%) 
resulting in a supernatant and a pellet. Analysis of the supernatant yields free 
carnitine and, after alkaline hydrolysis, total acid soluble carnitine. The pellet yields 
the long-chain acylcarnitines after alkaline hydrolysis (acyl group chain length ≥10 
carbons). The short-chain acylcarnitine fraction (acyl group chain length <10 
carbons) can be calculated from the difference between total acid soluble and free 
carnitine. The sum of total acid soluble and long-chain acylcarnitines represents the 
total carnitine content. 
 
Histological analysis of liver tissue 
Pieces of liver and skeletal muscle fixed in 4% formaldehyde were used for staining 
with hematoxilin-eosine for histological analysis. The frozen tissue was cut into 
sections and stained with Sudan Black B for the visualization of fat (Lison, 1934). The 
estimation of fat accumulation in the liver was carried out by light microscopy of the 
stained sections.  
 
Statistical analysis 
All analyses were performed in duplicate. For each treatment group (n=5 per group) 
the results are presented as mean ± SD. Significant differences between groups 
were determined by ANOVA/Bonferroni multiple comparison post hoc test. P values 
<0.05 were considered to be statistically significant. 
 
6.4 Results 
 
The aim of the current study was to characterize carnitine homeostasis and energy 
metabolism in OCTN2-deficient (homozygous jvs-/-) mice during carnitine deprivation 
and to compare the findings with heterozygous jvs+/- and wild type mice. 
 
Body and liver weight 
As shown in Table 1, there was no difference in the body weight at the end of the 
study between wild type, heterozygous jvs+/- and homozygous jvs-/- mice, and 
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carnitine deprivation did not affect body weight. Liver weight was increased by 14% in 
homozygous jvs-/- mice as compared to heterozygous jvs+/- mice, but not 
significantly different from wild type mice. Homozygous jvs-/- mice showed a further 
significant increase in their liver weights during carnitine deprivation, reaching 
approximately 15% after 6 or 10 days of carnitine withdrawal compared to jvs-/- mice 
supplemented with carnitine. 
 
Glycogen, lactate and ATP in liver and muscle 
As shown in Table 1, homozygous jvs-/- revealed a 215% increase in the hepatic 
glycogen content as compared to wild type mice and a 108% increase compared to 
heterozygous jvs+/- mice. After carnitine deprivation, the hepatic glycogen content 
did not change significantly. On the other hand, the skeletal muscle glycogen content 
was not significantly different between wild type mice, heterozygous jvs+/- and 
homozygous jvs-/- mice, but was decreased by 53% after 3 and 6 days of carnitine 
deprivation and by 55% after 10 days of carnitine deprivation. The liver lactate 
content was decreased in homozygous jvs-/- mice compared to heterozygous jvs+/- 
(67% decrease) or wild type mice (72% decrease). After carnitine deprivation, the 
liver lactate content showed no further decrease in homozygous jvs-/- mice. In 
contrast, the skeletal muscle lactate content was not different between homozygous 
jvs-/-, heterozygous jvs+/- and wild type mice, and significantly increased during 
carnitine deprivation in homozygous jvs-/- mice. This increase reached 154% after 6 
days and 338% after 10 days of carnitine withdrawal. Hepatic ATP levels were 
approximately doubled in homozygous jvs-/- mice compared to heterozygous jvs+/- 
or wild type mice, and remained constant 6 and 10 days after carnitine withdrawal. In 
contrast, the ATP content in skeletal muscle was slightly decreased in homozygous 
jvs-/- mice compared to wild type mice (decrease by 37%), but not significantly 
different from heterozygous jvs+/- mice. Similar to liver, carnitine deprivation did not 
significantly affect the skeletal muscle ATP content in homozygous jvs-/- mice. 
 
β-Hydroxybutyrate in plasma 
The plasma β-hydroxybutyrate concentration was decreased by 53% in homozygous 
jvs-/- mice compared to wild type or heterozygous jvs+/- mice. As expected, the 
plasma β-hydroxybutyrate concentrations showed a further drop with carnitine 
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deprivation in homozygous jvs-/- mice, reaching almost undetectable levels 10 days 
after carnitine withdrawal (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma carnitine pool 
As shown in table 2, the free carnitine levels in plasma were significantly lower in 
heterozygous jvs+/- mice (decrease by 42%) and homozygous jvs-/- (decrease by 
62%) compared to wild type mice. After carnitine deprivation, the plasma free 
carnitine concentration showed a further decrease in homozygous jvs-/- mice, 
reaching a concentration of 1 µmol/L after carnitine withdrawal for 10 days. Similar 
results were obtained for the other carnitine fractions, namely short- and long-chain 
acylcarnitines and total carnitine. Interestingly, the ratio short-chain acylcarnitines to 
total acid soluble carnitine increased significantly in homozygous jvs-/- mice after 
carnitine withdrawal. 
 
 
 
 
 
 
     Wild type  Heterozygous    Homozygous (jvs-/-)  
    (jvs+/+)  (jvs+/-)   basal  day3  day6  day10 
Free Carnitine    28.9±1.7  16.8±1.5*  11.1±1.0*§ 1.2±0.7† 1.5±0.2† 1.0±0.2† 
SCA Carnitine    4.7±2.1  2.7±1.7  0.4±0.2* 2.0±0.9 1.0±0.4 0.8±0.2 
TAS Carnitine    33.6±0.9  19.5±1.2*  11.5±0.9*§ 3.2±0.6† 2.5±0.3† 1.8±0.2† 
LCA Carnitine    7.6±0.5  7.1±0.5  5.8±0.7*§ 2.7±0.6 2.6±0.2 0.5±0.3 
SCA/TAS Carnitine   0.14±0.06  0.13±0.08  0.03±0.02 0.54±0.20† 0.39±0.15† 0.46±0.09† 
Total Carnitine   41.2±0.9  26.6±1.5*  17.3±1.2*§ 5.9±0.4† 5.1±0.4† 2.3±0.5† 
*p<0.05 vs. jvs+/+, † p<0.05 vs. jvs-/-, § p<0.05 vs. jvs+/- 
Table 2: Plasma concentration of carnitine. The mice were starved overnight before the final experiments, n = 5 for each group. The carnitine 
concentrations are expressed as µmol/L. Homozygous jvs-/- mice were studied while treated with carnitine (basal), and 3, 6 and 10 days after 
carnitine deprivation. Results are presented as mean±SD. LCA, long-chain-acylcarnitines; SCA, short-chain-acylcarnitines; TAS, total acid soluble 
carnitine. 
 
     Wild type  Heterozygous    Homozygous (jvs-/-)  
     (jvs+/+)  (jvs+/-)   basal  day3  day6  day10 
Body weight (g)   18.1±3.3  18.2±0.7  18.1±2.9 18.4±0.6 18.3±0.9 18.5±2.0 
Liver weight (% body weight)  5.8±0.4  5.4±0.4  6.1±0.4§ 6.1±0.7 7.0±0.3† 7.0±0.4† 
Glycogen in liver (µmoles/g)  35.6±17.2  53.9±14.3  112.1±17.9*§ 107.8±23.9 94.3±26.2 83.4±13.5 
Glycogen in muscle (µmoles/g) 31.1±2.7  34.8±3.5  32.0±1.9 15.1±1.8† 14.9±4.9† 14.5±3.4† 
Lactate in liver (µmoles/g)  12.1±2.4  10.4±4.2  3.4±1.8*§ 5.9±2.8 4.0±2.0 6.3±2.4 
Lactate in muscle (µmoles/g) 3.8±1.4  3.4±1.1  4.8±3.1 10.0±3.0 12.2±1.7† 21.0±3.3† 
ATP in liver (µmoles/g)  1.4±0.2  1.3±0.2  2.5±0.6*§ 1.0±0.2† 3.2±0.6 2.4±0.6 
ATP in muscle (µmoles/g)  3.8±0.9  2.7±0.4  2.4±0.8* 2.0±0.8 2.4±1.1 3.1±1.0 
ß-Hydroxybutyrate in plasma  220±20  230±20  100±20*§ 66±14† 45±7†  27±4† 
(µmol/l) 
* p<0.05 vs. jvs+/+, † p<0.05 vs. jvs-/-, § p<0.05 vs. jvs+/- 
Table 1: Characterization of the animals. The mice were starved overnight before the final experiments, n = 5 for each group. Tissue 
concentrations are expressed per g tissue wet weight. Homozygous jvs-/- mice were studied while treated with carnitine (basal), and 3, 6 and 10 
days after carnitine deprivation. Results are presented as mean±SD. 
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Liver carnitine pool 
As shown in Table 3, the free carnitine content in the liver was not different between 
wild type, heterozygous jvs+/- and homozygous jvs-/- mice. After carnitine  
 
withdrawal, there was a rapid and significant drop in the hepatic free carnitine content 
in homozygous jvs-/- mice, resulting in free carnitine levels in the range of 40 to 50% 
percent of those in homozygous jvs-/- mice. Similar results were obtained for the 
other carnitine fractions, i.e. short- and long-chain acylcarnitines and total carnitine. 
The ratio between free carnitine and short-chain acylcarnitines did not show 
significant differences between wild type, heterozygous jvs+/- and homozygous jvs-/- 
mice, but had a tendency to increase after carnitine withdrawal in homozygous jvs-/- 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skeletal muscle carnitine pool 
In contrast to liver, the free carnitine content in skeletal muscle was decreased in 
heterozygous jvs+/- (decrease by 24%) and in homozygous jvs-/- mice (decrease by 
33%) as compared to wild type mice. Similar to liver, carnitine deprivation was 
associated with a significant decrease in the skeletal muscle carnitine content in 
homozygous jvs-/- mice. After 10 days of carnitine withdrawal, the skeletal muscle 
carnitine content had dropped to 35% of the level in homozygous jvs-/- mice 
supplemented with carnitine. Similar results were obtained for the other carnitine 
     Wild type  Heterozygous    Homozygous (jvs-/-)  
     (jvs+/+)  (jvs+/-)   basal  day3  day6  day10 
Free Carnitine    143±22  124±14  133±18  44±19† 37±11† 51±7† 
SCA Carnitine    198±38  194±36  176±23 141±18  129±27† 97±26† 
TAS Carnitine    341±20  318±26  309±13 185±10† 166±16† 148±28† 
LCA Carnitine    95±11   79±16   55±12  46±7  41±8  38±7† 
SCA/TAS Carnitine   0.58±0.08  0.61±0.07  0.57±0.06 0.76±0.10† 0.77±0.08† 0.67±0.05 
Total Carnitine   436±11  397±39   363±22* 230±10† 207±16† 186±32† 
*p<0.05 vs. jvs+/+, † p<0.05 vs. jvs-/-, § p<0.05 vs. jvs+/- 
Table 3: Liver carnitine content. The mice were starved overnight before the final experiments, n = 5 for each group. The carnitine content is 
expressed as nmol/g wet tissue. Homozygous jvs-/- mice were studied while treated with carnitine (basal), and 3, 6 and 10 days after carnitine 
deprivation. Results are presented as mean±SD. LCA, long-chain-acylcarnitines; SCA, short-chain-acylcarnitines; TAS, total acid soluble carnitine 
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fractions, i.e. short- and long-chain acylcarnitines and total carnitine. Similar to liver, 
the ratio between free carnitine and total acid soluble carnitine increased with 
carnitine deprivation, reaching significance 10 days after carnitine withdrawal. 
 
Kinetics of total carnitine loss 
As shown in figure 1, the velocity of the drop in the total carnitine levels is different 
between plasma, liver and skeletal muscle. As expected when renal reabsorption of 
carnitine is lacking, the carnitine concentration drops most rapidly in plasma. 
Interestingly, the initial drop in the tissue carnitine content was faster in liver than in 
skeletal muscle, suggesting that export of carnitine and acylcarnitines from 
hepatocytes is easier than from myocytes. Ten days after carnitine withdrawal, the 
tissue content was still in the range of 60-70% percent of the initial values, 
demonstrating that the plasma membranes represent a strong barrier for cellular 
carnitine excretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Carnitine plasma and tissue stores after cessation of carnitine treatment in homozygous jvs-
/- mice. After carnitine deprivation, there is a rapid fall in the plasma total carnitine content, whereas 
the tissue carnitine content falls less rapidly. The fractional elimination rate of carnitine from skeletal 
muscle is in the order of 4% per day or 0.2% per hour. 
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Microvesicular liver steatosis 
Microvesicular liver steatosis, a consequence of impaired hepatic β-oxidation 
(Fromenty and Pessayre, 1995; Spaniol et al., 2001b), is a hallmark of homozygous 
jvs-/- mice (Koizumi et al., 1988; Kaido et al., 1997). As shown in Figure 2, 
microvesicular steatosis was much more accentuated in homozygous jvs-/- mice as 
compared to wild type or heterozygous jvs+/- mice. After carnitine withdrawal, 
microvesicular liver steatosis increased proportionally with the duration of carnitine 
deprivation. Accordingly, the highest fat content was observed in livers from 
homozygous jvs-/- mice 10 days after carnitine withdrawal. 
 
 
 
Figure 2: Hepatic accumulation of fat in wild type (A), heterozygous jvs+/- (B) and homozygous-/- mice 
before (C) and after carnitine deprivation for 3 (D), 6 (E) and 10 days (F). Homozygous jvs-/- mice 
reveal a slight increase in the hepatic fat content compared to wild type or heterozygous jvs+/- mice. 
Carnitine deprivation is associated with a rapid and massive increase in the hepatic fat content in 
homozygous jvs-/- mice. Sudan Black B stain, magnification 63x, the micron bars represent 25 µm. 
A 
B 
C 
D 
E 
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6.5 Discussion 
 
While the free and total carnitine plasma concentrations were clearly decreased in 
heterozygous jvs+/- and carnitine-treated homozygous jvs-/- mice compared to wild 
type mice, the tissue carnitine pool was not decreased in heterozygous jvs+/- mice 
and only slightly decreased in carnitine-treated homozygous jvs-/- mice. These 
findings suggest that the plasma membranes of hepatocytes and myocytes are quite 
resistant for the transport of carnitine, protecting the tissues from carnitine losses. 
This statement is underscored by the findings during carnitine deprivation in 
homozygous jvs-/- mice. While the plasma carnitine concentration decreased rapidly 
in jvs-/- mice after cessation of carnitine administration, the carnitine tissue levels 
showed a much slower decrease (see Figure 1). 
The rapid fall in the plasma carnitine concentration after carnitine deprivation could 
be expected, since the renal carnitine excretion fraction of carnitine increases from 
<0.05 to approximately 1 in patients or mice with systemic carnitine deficiency 
(Treem et al., 1988; Kuwajima et al., 1991), demonstrating that OCTN2 is the most 
important or even the only carrier for renal reabsorption of carnitine. Since carnitine is 
a polar molecule, transporters are needed for its efficient transition across biological 
membranes. Taking into account the large concentration difference between the 
intracellular and the plasma carnitine levels (between 1 and 2 orders of magnitude) 
and in vitro findings with isolated rat skeletal muscle (Brass et al., 1993), diffusion 
may also play a role. While the transport into cells is mediated by OCTN2 and 
possibly other carriers, which use the sodium gradient between plasma or interstitial 
fluid and the intracellular milieu as a driving force (Stieger et al., 1995; Tamai et al., 
1998; Berardi et al., 2000), the export of carnitine from cells has so far not been 
characterized on the molecular level. In perfused rat livers, an active transport 
mechanism has been described, which can be blocked by mersalyl but not oubain 
and which has a Km in the range of 300 µmol/L and a maximal transport capacity of 
approximately 2.5 nmol/g liver per minute (Sandor et al., 1985). Using these values, 
the livers of the jvs-/- mice (weighing 1 to 1.5 g) should have been completely 
carnitine-depleted in less than 3 hours after carnitine deprivation. In contrast to this 
prediction, the livers of jvs -/- mice had lost only approximately 50% of their carnitine 
stores after carnitine deprivation for 10 days. Assuming that the observations 
reported in the literature are correct and that the data obtained in rats are also valid 
for mice, two explanations can be offered to resolve this apparent discrepancy. The 
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first one is uptake of a sufficient amount of carnitine by the food. Mice eat per day 
approximately 10% of their body weight (approximately 2g per day) and the food for 
rodents used by us contains approximately 15 nmoles carnitine per g (Spaniol et al., 
2003), resulting in a daily carnitine ingestion of approximately 30 nmoles. This 
amount is lower than the daily excretion in the urine, which is in the range of 100 
nmoles/day for wild type or heterozygous jvs -/+ mice (Knapp AC and Krähenbühl S, 
unpublished results) or even higher in jvs -/- mice (Horiuchi et al., 1994). Carnitine 
intake by the food is therefore not sufficient to explain our findings. A second possible 
explanation is hepatic carnitine biosynthesis. In rodents, the liver is the most 
important organ for the final step in carnitine biosynthesis, the conversion of 
butyrobetaine to carnitine (Krahenbuhl et al., 2000b). Butyrobetaine is formed in most 
tissues by trimethylation of protein-bound lysine, which is subsequently transformed 
over several steps (including proteolysis and decarboxylation) to butyrobetaine 
(Hoppel and Davis, 1986; Krahenbuhl et al., 2000b; Vaz and Wanders, 2002). Since 
the highest amount of butyrobetaine is formed in skeletal muscle (Davis and Hoppel, 
1986; Krahenbuhl et al., 2000b), butyrobetaine would have to be transported from 
skeletal muscle into the liver, where it is hydroxylated to carnitine. Similar to carnitine, 
the transport into the liver is active and sodium-dependent, and has a Km in the range 
of 5 µmol/L (Berardi et al., 1998), suggesting that butyrobetaine is transported by a 
carrier similar to or identical with OCTN2. Since jvs -/- mice are able to form carnitine 
from butyrobetaine in vivo (Higashi et al., 2001), it can be assumed, however, that 
other transporters than OCTN2 exist that can transport butyrobetaine at a sufficient 
amount into the liver. Hepatic synthesis of carnitine is therefore a possible 
explanation for the slow decrease of the hepatic carnitine stores in jvs -/- mice. 
On the other hand, the slow decay of the carnitine content in skeletal muscle could 
be expected. Rebouche et al. have investigated the export of carnitine from tissues 
such as skeletal muscle in humans with or without carnitine deficiency and have 
described a fractional elimination rate in the range of 0.5% per hour (Rebouche and 
Engel, 1984). In our studies, the fractional elimination rate of carnitine from skeletal 
muscle is in the range of 4% per day or approximately 0.2% per hour, which is close 
to the values reported by Rebouche et al. (Rebouche and Engel, 1984). These 
observations show directly that the tissue carnitine stores are tried to be kept at a 
high level as long as possible by a high resistance of the plasma membranes for 
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carnitine transport and possibly also by synthesis of carnitine in specific tissues such 
as the liver. 
Nevertheless, these measures are not sufficient to keep the carnitine tissue stores at 
a high enough level to avoid negative consequences on energy metabolism in jvs -/- 
mice. While carnitine-treated jvs-/- mice had lower β-hydroxybutyrate plasma levels 
after starvation for 12 h than wild type or heterozygous jvs-/+ mice (suggesting 
impaired hepatic β-oxidation (Brass and Hoppel, 1978), accumulation of hepatic fat 
was not dramatic and skeletal muscle energy metabolism was not disturbed. After 
cessation of carnitine treatment, however, plasma β-hydroxybutyrate levels fell 
rapidly and hepatic accumulation of fat increased dramatically, suggesting that 
hepatic β-oxidation had almost vanished. Nevertheless, jvs-/- mice were still able to 
maintain the tissue ATP levels up to 10 days of carnitine deprivation. In skeletal 
muscle, glycogenolysis and glycolysis were increased as suggested by the 
decreasing tissue glycogen content and increasing lactate concentrations after 
cessation of carnitine administration. Lactate produced in skeletal muscle may have 
been transported to the liver for gluconeogenesis, possibly explaining the increased 
hepatic glycogen stores in jvs -/- mice, which were quite resistant to carnitine 
deprivation. 
In conclusion, the current studies show directly that the carnitine tissue stores are 
maintained over a long time after cessation of carnitine administration in jvs -/- mice 
due to the tightness of the plasma membranes towards transition of carnitine and 
most probably also due to hepatic carnitine biosynthesis. Nevertheless, the 
consequences of carnitine depletion on fatty acid and carbohydrate metabolism 
appear rapidly after cessation of carnitine administration in jvs -/- mice, showing that 
the margin between apparent well functioning and demise of energy metabolism is 
very narrow in mice, and possibly also humans, with systemic carnitine deficiency. 
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7.1 Abstract 
 
The aims of this study were to investigate whether carnitine deficiency is a risk factor 
for valproate (VPA)-associated hepatotoxicity and to explore the effects of VPA on 
carnitine plasma and tissue stores in mice with carnitine deficiency. Therefore, we 
treated heterozygous jvs+/- mice, an animal model for systemic carnitine deficiency 
due to impaired renal reabsorption of carnitine, and the corresponding wild type mice 
with subtoxic oral doses of VPA (100 mg/kg bw) for 2 weeks. In jvs+/- mice, but not in 
wild type mice, treatment with VPA was associated with increased serum activities of 
aspartate aminotransferase and alkaline phosphatase, reduced palmitate metabolism 
assessed in vivo and microvesicular steatosis of the liver. Creatine kinase activities 
were not affected by treatment with VPA. In isolated liver mitochondria, VPA was 
associated with decreased oxidative metabolism of L-glutamate, succinate and 
palmitate as well as impaired β-oxidation of palmitate, both in wild type and jvs+/- 
mice. In comparison to vehicle-treated wild type mice, vehicle-treated jvs+/- mice had 
decreased carnitine plasma, liver and skeletal muscle levels. Treatment with VPA 
was associated with further substantial decreases in carnitine plasma and tissue 
levels and with a shift of the carnitine pools towards short-chain acylcarnitines. We 
conclude that jvs+/- mice reveal a more accentuated hepatic toxicity by VPA than the 
corresponding wild type mice. Systemic carnitine deficiency can therefore be 
regarded as a risk factor for hepatotoxicity associated with VPA. 
 
7.2 Introduction 
 
Valproic acid (N-dipropylacetic acid) or valproate (VPA) is a branched, medium-chain 
fatty acid composed of eight carbons, which is structurally unrelated to other 
antiepileptic drugs. VPA is a broad-spectrum antiepileptic drug which was introduced 
into the anticonvulsant market in 1968 in Europe and 10 years later in the United 
States (Zafrani and Berthelot, 1982). Shortly after introduction, cases of fulminant 
liver failure in patients treated with VPA have been reported (Zafrani and Berthelot, 
1982; Zimmerman and Ishak, 1982; Dreifuss et al., 1987; Konig et al., 1994; 
Krahenbuhl et al., 1995), but the underlying mechanism of VPA induced 
hepatotoxicity is still not fully understood. One principal cause of liver failure 
associated with VPA therapy is most probably the inhibition of hepatic mitochondrial 
β-oxidation. Microvesicular steatosis of the liver, one of the most important 
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histological findings in VPA-induced liver failure (Zafrani and Berthelot, 1982; 
Zimmerman and Ishak, 1982; Dreifuss et al., 1987; Krahenbuhl et al., 1995), is 
considered to result from impaired hepatic β-oxidation (Fromenty and Pessayre, 
1995; Spaniol et al., 2001b). Different mechanisms have been proposed explaining 
inhibition of mitochondrial β-oxidation by VPA, among them microsomal production of 
toxic metabolites, e.g., 4-ene-VPA and 2,4-diene-VPA (Gram and Bentsen, 1985; 
Tennison et al., 1988; Ponchaut et al., 1992b; Ishikura et al., 1996), decreased 
activity of complex IV of the respiratory chain and/or depletion of the hepatic pools of 
coenzyme A and/or carnitine (Ponchaut and Veitch, 1993; Krahenbuhl et al., 1995). 
Pre-existing mitochondrial diseases, e.g. impaired β-oxidation or impaired function of 
the respiratory chain, have been proposed to represent risk factors for VPA-
associated mitochondrial dysfunction and therefore for liver failure (Chabrol et al., 
1994; Lam et al., 1997; Krahenbuhl et al., 2000a). Since carnitine is an essential 
cofactor for hepatic β-oxidation (Fromenty and Pessayre, 1995), systemic carnitine 
deficiency (SCD; OMIM 212140) is associated, among others, with microvesicular 
steatosis of the liver (Spaniol et al., 2001b). We therefore hypothesized that mice with 
SCD are more susceptible to hepatic and possibly also skeletal muscle adverse 
effects associated with VPA treatment compared to control mice. To test our 
hypothesis, we used juvenile visceral steatosis (jvs) mice (formerly named C3H-H-
2°), which were first described 1988 by Koizumi et al. (Koizumi et al., 1988). Jvs mice 
have a mutation in the gene coding for OCTN2 (Lu et al., 1998), leading to impaired 
renal absorption of carnitine and systemic carnitine deficiency. These mice are 
phenotypically characterized by liver steatosis and other features of carnitine 
deficiency such as hyperammonemia, hypoglycemia, cardiac hypertrophy, 
mitochondrial abnormalities in skeletal muscle and progressive growth retardation 
(Horiuchi et al., 1993; Kaido et al., 1997). For our studies, we used heterozygous 
(jvs+/-) and not homozygous (jvs-/-) mice, since the carnitine tissue levels of jvs+/- 
mice are approximately half of wild type mice and, in contrast to homozygous jvs-/- 
mice, jvs+/- mice can survive without carnitine replacement. An additional question 
that we wanted to address with our studies was the effect of VPA on carnitine 
homeostasis in an animal model with decreased carnitine stores such as jvs-/+ mice. 
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7.3 Materials and Methods 
 
Reagents 
[1-14C] palmitic acid was purchased from Amersham Pharmacia Biotech (Dübendorf,  
Switzerland). Sodium valproate (VPA) and all other chemicals used in this study were 
obtained from Sigma Aldrich (Buchs, Switzerland) and were of the highest purity 
available. 
 
Animals 
The juvenile visceral steatosis (jvs) mice were obtained from Prof. Masahisa Horiuchi 
from the University of Kagoshima, Japan. The breeding pairs (wild type and jvs+/- 
mice) and the offsprings were supplemented with carnitine (1g/250ml drinking water) 
before weaning to maintain an optimal survival rate. After weaning, the 
supplementation with carnitine was continued for the homozygous jvs-/- mice. For 
genotyping the littermates (wild type, jvs+/- and jvs-/- mice), DNA was extracted and 
purified from the mouse tails with a DNA extraction kit (kit No. 740952.250, 
Macherey-Nagel, Oensingen, Switzerland) and analyzed using a TaqMan allelic 
discrimination method, which combines PCR and mutation detection in a single step. 
Two allele-specific TaqMan probes were used, one for each allele (Applied 
Biosystems, UK). Each probe consisted of an oligonucleotide with a 5’ reporter dye 
(FAM for the detection of the wild type L352 allele and VIC for the detection of the 
mutant L352R allele) and a 3’ quencher dye (TAMRA for both probes). The probes 
were as follows: FAM, 5’-atatggtcagcctgca-3’ and VIC, 5’-tatggtccgcctgca-3’. The 
primers used (Microsynth, Switzerland) were identically for both alleles and were 
designed as follows: forward primer, 5’-tccccatgcaagttaggagtgt-3’, reversed primer, 
5’-tgctgctccagctctcttctg-3’. TaqMan analysis was carried out on a 7900HT Sequence 
Detection System (Applied Biosystems, Rotkreuz, Switzerland) and identification of 
the mutation in Octn2 was achieved using an allelic discrimination plot (Todesco et 
al., 2003). Cycling conditions were 10 min at 95°C for initial denaturation and 
activation of the DNA polymerase, followed by 40 cycles of 15 s at 95°C for 
denaturation and 1 min at 60°C for combined anneali ng and primer extension. 
Fluorescence from the FAM reporter only reflects the presence of wild type alleles, 
whereas fluorescence from the VIC reporter only indicates mutant alleles. 
Accordingly, fluorescence from both reporters reflects the heterozygous population.  
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All experiments had been reviewed and accepted by the Animal Ethics Committee of 
the canton Basel Stadt. Experiments were performed with animals 9 to 12 weeks old. 
 
Study design and VPA administration 
 
For this study, 4 groups of jvs mice were investigated. Wild type mice treated with 
VPA or 0.9% NaCl (vehicle), and heterozygous jvs+/- mice treated with VPA or 0.9 % 
NaCl (n=5 per group). VPA (0.1 mg/g body weight/day) or vehicle were administered 
p.o. in a volume of 10 µl/g body weight once a day for 2 weeks. The used VPA dose 
was subtoxic, as established in earlier studies (Letteron et al., 1996; Schnackenberg 
et al., 2006). The mice were starved overnight before being used for the experiments. 
Urine of the mice was collected individually for 24 hours and a blood sample was 
obtained from the tail vein before the mice were killed by decapitation. Tissue 
samples were obtained from the liver and skeletal muscle (quadriceps femoris) for 
carnitine analysis. These samples were quickly frozen in liquid nitrogen and stored at 
-80°C until analysis. Additional liver samples were  treated with 4% formaldehyde for 
histological analysis after staining with hematoxylin-eosin or with Sudan Black B. The 
remainder of the liver was quickly removed, put on ice and used for the isolation of 
mitochondria.  
 
Characterization of the animals 
The animals were characterized by their body and liver weights, activities of 
aspartate aminotransferase, alkaline phosphatase and creatine kinase. These 
parameters were analyzed with commercially available kits on a MODULAR analyzer 
(Hoffmann-La Roche Diagnostics, Basel, Switzerland). 
 
In vivo oxidation of palmitate 
To collect breath of the mice, they were placed in a cylindrical vessel attached to a 
vacuum pump. [1-14C] palmitic acid (3 µCi/kg, 57.0 mCi/mmol) was diluted in thistle 
oil and administered i.p. at 0 min. To collect the 14CO2 resulting from the oxidation of 
[1-14C] palmitate, the exhaled air was pulled through successive solutions of ethanol 
(to dry the exhaled breath) and ethanolamine (4M in ethanol) to trap exhaled 14CO2. 
The exhaled 14CO2 was quantified over 120 min by scintillation spectroscopy. 
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Isolation of liver mitochondria 
The mitochondrial fraction of mouse livers was obtained by differential centrifugation 
according to the method of Hoppel (Hoppel et al., 1979). The mitochondrial protein 
content was determined using the biuret method with BSA as a standard (Gornall et 
al., 1949). 
 
Oxygen consumption and in vitro β-oxidation of intact mitochondria 
Oxygen consumption by freshly isolated liver mitochondria was measured in a 
chamber equipped with a Clark-type oxygen electrode (Yellow Springs Instruments, 
Yellow Springs, OH) at 30°C as described previously  (Hoppel et al., 1979). The 
concentrations of the substrates were 20 mmol/l for L-glutamate and succinate, and 
40 µmol/l for palmitoyl-CoA. The incubation with palmitoyl-CoA contained in addition 
2 mmol/l L-carnitine and 5 mmol/l L-malate.  
 
In vitro β-oxidation of intact mitochondria 
The β-oxidation of [1-14C] palmitic acid by liver mitochondria, which measures the 
formation of acid-soluble products from mitochondrial palmitate metabolism, was 
determined with freshly isolated liver mitochondria according to the method of 
Freneaux et al. (Freneaux et al., 1988) with some modifications as described by 
Spaniol et al. (Spaniol et al., 2001a).  
 
Determination of carnitine in plasma, tissue and urine 
The carnitine concentrations in plasma, liver, muscle and urine were determined 
radioenzymatically as described by Brass and Hoppel (Brass and Hoppel, 1978). 
Plasma and tissue samples were treated with perchloric acid (final concentration 
3%), resulting in a supernatant and a pellet. Analysis of the supernatant yields free 
carnitine and, after alkaline hydrolysis, total acid soluble carnitine. The pellet yields 
the long-chain acylcarnitines (acyl group chain length ≥10 carbons) after alkaline 
hydrolysis. The short-chain acylcarnitine fraction (acyl group chain length <10 
carbons) can be calculated from the difference between total acid soluble and free 
carnitine, and the sum of total acid soluble and long-chain acylcarnitine represents 
total carnitine.  
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Histological analysis of liver tissue 
Pieces of the liver were fixed in 4% formaldehyde for histological analysis after 
staining with hematoxylin-eosin or immunohistochemistry for caspase 3. 
For caspase 3 staining, paraffin sections were rehydrated and heated in EDTA buffer 
(pH 8.0; 100°C/ 5min). Slides were then incubated i n a quench solution (1.0 M 
sodium azide in a solution of 4:1 methanol and 30% hydrogen peroxide, v:v) and 
after that incubated with blocking solution (normal goat serum) for 30min. Next, 
sections were incubated with caspase-3 antibody (cleaved caspase-3 antibody from 
Cell Signalling Technology, Beverly, MA, USA) diluted 1:100 in a phosphate-buffered 
saline pH 7.1–7.3 (Antibody Diluting Buffer, ChemMate, Ventana Medical Systems, 
Illkirch, France) for 1h at room temperature. Negative controls were performed by 
omitting the primary antibody. Following primary antibody incubation, slides were 
washed three times with TBS containing 0.05% Tween 20, and then incubated for 
30min at room temperature with a cocktail of biotinylated secondary antibodies in 
Antibody Dilution Buffer. The slides were again washed and then incubated for 30 
minutes at room temperature with avidin-biotin complex (Vectastain Elite ABC kit, 
Vector, Burlingame, CA, USA). Staining was visualized by incubating for 10min in 
DAB solution (K3466, Dako, Baar, Switzerland), after which the slides were rinsed in 
water, counterstained with hematoxylin, dehydrated and coverslipped.  
The frozen liver tissue was cut into sections and stained with Sudan Black B (Lison, 
1934) for the determination of fat accumulation. The estimation of fat accumulation 
and the investigation of pathological changes in the liver were carried out by light 
microscopy of the stained sections. 
 
Statistical analysis 
All analyses were performed in duplicate. For each treatment group (n=5 per group) 
the results are presented as mean ± SD. Significant differences between groups 
were determined by ANOVA/Bonferroni multiple comparison post hoc test. P values 
<0.05 were considered to be significant. 
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7.4 Results 
 
The aims of this study were to investigate whether moderate carnitine deficiency is a 
risk factor for VPA-associated hepatotoxicity and possibly myotoxicity, and to explore 
the effect of VPA on carnitine homeostasis in jvs-/+ mice. 
 
Body and liver weight, biochemical parameters 
As shown in Table 1, no difference was found in the body weight before and at the 
end of the study between wild type and jvs+/- mice. Treatment with VPA had no 
significant effect on body weight. Liver weight adjusted to body weight was increased 
by 25% in jvs+/- mice treated with VPA compared to jvs+/- mice treated with vehicle. 
In contrast, treatment with VPA did not affect liver weight in wild type mice. In 
comparison to wild type mice treated with VPA, jvs+/- mice treated with VPA showed 
an increase of 49% in aspartate aminotransferase activity and of 50% in alkaline 
phosphatase activity. In comparison to vehicle-treated jvs+/- mice, this increase was 
110% for aspartate aminotransferase and 68% for alkaline phosphatase. Activities of 
creatine kinase were not significantly different between the groups, suggesting that 
carnitine status and/or treatment with VPA had no significant effect on skeletal 
muscle. 
 
 
 
 
 
 
 
 
 
 
 
 
In vivo oxidation of palmitate 
As shown in figure 1, VPA-treated jvs+/- mice showed a lower peak exhalation of 
14CO2 (30 min after injection) compared to vehicle-treated jvs+/- mice (21% 
decrease) and to VPA-treated wild type mice (20 min after injection, 23% decrease). 
 Wild type (jvs+/+)      Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
Body weight (start of study) (g) 20.6 ± 1.8 19.3 ± 1.5 22.7 ± 4.0 17.8 ± 2.5 
Body weight (end of study) (g) 21.0 ± 2.2 19.7 ± 1.4 22.9 ± 3.7 18.0 ± 2.6 
Liver weight (mg per g body weight) 41.6 ± 3.2 45.4 ± 3.5 41.0 ± 4.7 51.2 ± 2.3# 
Aspartate aminotransferase (U/l) 49 ± 14 69 ± 18 49 ± 11 103 ± 8†,# 
Alkaline phosphatase (U/l) 58 ± 10 82 ± 12 73 ± 19 123 ± 17†,# 
Creatine kinase (U/l) 101 ± 50 115 ± 60 95 ± 40 123 ± 47 
† p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
Table 1: Characterization of the animals. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and jvs+/-
mice were treated orally with normal saline or VPA for 14 days. Results are presented as mean±SD. 
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Additionally, the exhalation of 14CO2 over 2 hours was significantly lower in VPA-
treated jvs+/- mice. The decrease reached 23% compared to vehicle-treated jvs+/- 
mice and 20% compared to VPA-treated wild type mice. On the other hand, there 
was no difference in these parameters between vehicle-treated wild type mice and 
vehicle-treated jvs+/- mice, as well as between vehicle-treated and VPA-treated wild 
type mice. These findings indicate that both carnitine deficiency and treatment with 
VPA are necessary to impair hepatic β-oxidation in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: In vivo palmitate metabolism by wild type or jvs+/- mice treated with oral saline or VPA (100 
mg/kg body weight) for 14 days. A trace amount of [1-14C] palmitic acid was injected intraperitoneally 
and exhalation of 14CO2 was determined over 2 hours. VPA-treated jvs+/- mice show a lower peak 
exhalation of 14CO2 (after 30 min) compared to vehicle-treated jvs+/- mice, vehicle-treated wild type 
mice or VPA-treated wild type mice (8.6 ± 0.3 vs. 10.6 ± 0.4, 11.3 ± 0.8 or 10.7 ± 0.3% of dose per 10 
min, respectively, p<0.05 against all other groups). In addition, the total amount of 14CO2 exhaled over 
2 hours was also less in VPA-treated jvs+/- mice compared to vehicle-treated jvs+/- mice, vehicle-
treated wild type mice or VPA-treated wild type mice (33.5 ± 4.2 vs. 41.8 ± 3.9, 46.5 ± 3.9 or 41.7 ± 
4.8% of dose, respectively, p<0.05 against all other groups). 
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Histological findings in the liver 
In agreement with in vivo β-oxidation, fat accumulation in liver was lowest in vehicle-
treated wild type mice (Figure 2A) and slightly higher in wild type mice treated with 
VPA or in vehicle-treated jvs-/+ mice (Figures 2B and C). The combination of 
carnitine deficiency (jvs-/+ mice) and treatment with VPA was associated with the 
highest extent of fat accumulation (Figure 2D). The accumulated fat was from the 
microvesicular type, compatible with impaired β-oxidation (Fromenty and Pessayre, 
1995; Spaniol et al., 2003). 
Stains with hematoxylin-eosin confirmed the presence of microvesicular steatosis 
predominantly in VPA-treated jvs+/- mice but showed only a small number of cells 
undergoing apoptosis (eosinophilic hepatocytes) (Figure 3A). Accordingly, only few 
cells were caspase-3 positive (Figure 3B), suggesting that apoptosis was rare, even 
in livers from VPA-treated jvs-/+ mice. Similar histological findings have been 
reported in another study (Jezequel et al., 1984). 
 
 
Figure 2: Hepatic accumulation of fat in vehicle-treated wild type (A), VPA-treated wild type (B), 
vehicle-treated jvs+/- mice (C) and VPA-treated jvs+/- mice (D). Vehicle-treated wild type livers contain 
only few hepatocytes with Sudan B stainable material (small intracellular dark droplets, see arrow) (A). 
VPA treatment of wild type mice for two weeks (B) or heterozygousity for OCTN2 (vehicle-treated 
jvs+/- mice) (C) is associated with a slight increase in microvesicular fat. VPA-treated jvs+/- mice show 
the highest accumulation of microvesicular fat, mainly in the pericentral region of liver lobules (D). 
Sudan black B staining, the micron bars represent 20 µm. 
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Figure 3: Histological changes in liver sections stained with hematoxylin-eosin and for caspase-3 in 
liver sections of VPA-treated jvs+/- mice. Staining with hematoxylin-eosin of livers from VPA-treated 
jvs+/- mice shows cytoplasmic vesicles compatible with microvesicular steatosis, mononuclear portal 
infiltrates (not shown) and occasional hypereosinophilic hepatocytes (3A). Staining with caspase-3 is 
slightly positive in such hepatocytes (3B), compatible with hepatocyte apoptosis. In sections of vehicle-
treated wild type livers no such changes could be observed. HE-staining, the micron bars represent 20 
µm. 
 
 
 
Oxygen consumption by isolated liver mitochondria 
Since impairment of mitochondrial function associated with VPA has been shown 
before (Ponchaut and Veitch, 1993), we examined the function of the respiratory 
chain in the presence of different substrates. As shown in table 2, the state 3 
oxidation rate of L-glutamate was decreased by 32% in VPA-treated compared to 
vehicle-treated wild type mice. Similarly, a decrease of 58% was found in VPA-
treated heterozygous jvs+/- versus vehicle-treated jvs+/- mice. The state 3 oxidation 
rate of succinate was also significantly lower in VPA-treated jvs+/- mice (decrease by 
52%) compared to vehicle-treated heterozygous jvs+/- mice, whereas no significant 
decrease was found in VPA-treated wild type compared to vehicle-treated wild type 
mice. Palmitoyl-CoA state 3 oxidation rates were decreased by 43% in VPA-treated 
wild type mice and by 73% in VPA-treated jvs+/- mice compared to their vehicle-
treated controls. 
 
In vitro β-oxidation by intact liver mitochondria  
Due to the fact that VPA has been shown to impair mitochondrial β-oxidation (Levy et 
al., 1990; Ponchaut et al., 1992b; Fromenty and Pessayre, 1995), we also 
investigated the effect of VPA on the metabolism of palmitate by isolated liver 
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mitochondria. As shown in table 2, VPA treatment significantly decreased palmitate 
oxidation by 44% in wild type and by 35% in jvs+/- mice compared to their vehicle-
treated controls. For the interpretation of these results, it is important to take into 
account that the experiments were performed under saturating conditions regarding 
palmitate and in the presence of exogenous L-carnitine, which is different from the in 
vivo palmitate oxidation experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma carnitine concentration 
As shown in table 3, the free and total carnitine levels in plasma were significantly 
lower in wild type mice treated with VPA compared to vehicle-treated wild type mice 
(decrease by 58% and 24%, respectively). Similar results were obtained for VPA-
treated jvs+/- mice, where the decrease was 65% for free carnitine and 39% for total 
carnitine, respectively, versus vehicle-treated jvs+/- mice. A comparison of VPA-
treated jvs+/- versus VPA-treated wild type mice revealed a decrease of 40% in free 
carnitine and a decrease of 37% in total carnitine in jvs+/- mice. Treatment with VPA 
was associated with a decrease in the total carnitine concentration in both groups, 
namely by 24% in wild type and by 39% in jvs+/- mice. Remarkably, the short-chain 
acylcarnitine/total acid soluble carnitine ratio showed a 120% increase in VPA-treated 
wild type and a 76% increase in VPA-treated heterozygous jvs+/- mice compared to 
their vehicle-treated controls. 
 
 Wild type (jvs+/+)      Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
State 3 oxidation rates  
L-Glutamate (20 mM) 56 ± 12 38 ± 8* 48 ± 8 28 ± 2# 
Succinate (20 mM) 120 ± 20 88 ± 28 122 ± 28 64 ± 10# 
Palmitoyl-CoA (40 µM) 42 ± 12 24 ± 8* 30 ± 8 8 ± 2†,# 
Mitochondrial ß-Oxidation  
ß-Oxidation of 14C-1-palmitate 0.27 ± 0.04 0.15 ± 0.02* 0.26 ± 0.04 0.17 ± 0.04# 
* p<0.05 Vehicle-treated jvs+/- or VPA-treated wild type vs. vehicle-treated wild type; † p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # 
p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
 
Table2: Function of mouse liver mitochondria. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and 
jvs+/- mice were treated orally with normal saline or VPA for 14 days. Mitochondria were isolated by differential centrifugation. State 3 oxidation 
rates were determined using different substrates and the in vitro ß-oxidation was measured with 14C-1-palmitate. Units are natoms oxygen/min/mg 
mitochondrial protein for the oxidation rates and nmol/min/mg mitochondrial protein for ß-oxidation. Results are presented as mean±SD. 
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Urinary excretion of carnitine 
As shown in table 4, treatment with VPA over two weeks was associated with an 
increased excretion of free carnitine in wild type and of free and total carnitine in 
jvs+/- mice. In jvs+/- mice treated with VPA, the excretion of free carnitine was 
increased by 114% compared to vehicle-treated jvs+/- mice, whereas the increase in 
total carnitine excretion was 108%. Compared to vehicle-treated control mice, the 
renal clearance of free carnitine was approximately 6-fold higher in VPA-treated 
jvs+/- mice and approximately 3-fold higher in VPA-treated wild type mice. 
 
 
 
 
 
 
 
 
 
 
 
 Wild type (jvs+/+)  Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
Free Carnitine 31.3 ± 2.7 13.1 ± 1.7* 22.4 ± 2.0* 7.9 ± 1.7†,# 
SCA Carnitine 10.1 ± 3.4 14.6 ± 2.1* 11.0 ± 1.5 11.1 ± 1.4 
TAS Carnitine 41.4 ± 1.2 27.6 ± 1.4* 33.6 ± 1.2* 19.0 ± 0.9†,# 
LCA Carnitine 6.6 ± 1.3 9.0 ± 0.9* 4.2 ± 1.2* 4.1 ± 0.5† 
SCA/TAS Carnitine 0.24 ± 0.08 0.53 ± 0.06* 0.33 ± 0.04 0.58 ± 0.08# 
Total Carnitine 48.0 ± 1.2 36.6 ± 2.3* 37.8 ± 2.2* 23.1 ± 1.2†,# 
* p<0.05 Vehicle-treated jvs+/- or VPA-treated wild type vs. vehicle-treated wild type; † p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # 
p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
 
Table 3: Plasma carnitine content. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and jvs+/- mice 
were treated orally with normal saline or VPA for 14 days. Carnitine was determined using a radioenzymatic method, units are µmol/L. Results are 
presented as mean ± SD. LCA, long-chain-acylcarnitine; SCA, short-chain-acylcarnitine; TAS, total acid soluble carnitine.  
 
 Wild type (jvs+/+)  Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
Free Carnitine 85.1 ± 11.0 102.8 ± 17.5 91.3 ± 25.5 195.8 ± 15.3†,# 
Total Carnitine 144.0 ± 12.1 137.5 ± 14.7 133.2 ± 34.7 277.4 ± 24.7†,# 
SCA Carnitine 58.9 ± 13.1 34.7 ± 7.4 41.9 ± 15.7 81.6 ± 19.1†,# 
Renal clearance, free carnitine 2.8 ± 0.5 8.0 ± 1.4* 4.10 ± 1.2 25.5 ± 5.10†,# 
* p<0.05 Vehicle-treated jvs+/- or VPA-treated wild type vs. vehicle-treated wild type; † p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # 
p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
 
Table 4: Urinary excretion of carnitine. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and jvs+/-
mice were treated orally with normal saline or VPA for 14 days. Carnitine was determined using a radioenzymatic method. Units are nmol/day for 
carnitine and ml/day for renal clearance of free carnitine. Results are presented as mean ± SD.  
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Liver carnitine content 
As shown in Table 5, the hepatic free carnitine content was 33% lower in vehicle-
treated jvs+/- compared to vehicle-treated wilt type mice. While treatment with VPA 
did not affect significantly the free carnitine content in wild type mice, VPA decreased 
the free carnitine content in jvs+/- mice by 53%. The short chain-acylcarnitine content 
was increased by VPA treatment by a factor of 2 to 3 in both wild type and jvs+/- 
mice compared to the respective vehicle-treated groups. Accordingly, the short-chain 
acylcarnitine/total acid soluble carnitine ratio was increased in both VPA-groups 
versus the vehicle-treated controls, reaching 157% in the wild type and 195% in 
jvs+/- mice, respectively. The total carnitine content was decreased by 26% in 
vehicle-treated jvs+/- compared to wild type mice. In both groups, treatment with VPA 
was not associated in significant changes in the total carnitine content. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Skeletal muscle carnitine content 
Free carnitine levels were not different between vehicle-treated wild type and jvs+/- 
mice. Treatment with VPA decreased the free carnitine content by 31% in jvs+/- 
mice, but had no significant effect in wild type mice. The short-chain acylcarnitine 
content and the short-chain acylcarnitine/total acid soluble carnitine ratio were not 
different between vehicle-treated wild type and jvs+/- mice and were not affected by 
 Wild type (jvs+/+)  Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
Free Carnitine 200.6 ± 43.1 166.6 ± 40.6 134.3 ± 24.7* 63.7 ± 12.2†,# 
SCA Carnitine 31.8 ± 17.6 93.0 ± 26.9* 31.2 ± 15.3 82.6 ± 16.4# 
TAS Carnitine 232.5 ± 27.0 259.7 ± 32.6 165.8 ± 11.4* 146.3 ± 14.0† 
LCA Carnitine 71.1 ± 4.7 59.6 ± 2.4* 57.8 ± 3.4* 49.7 ± 5.4†,# 
SCA/TAS Carnitine 0.14 ± 0.09 0.36 ± 0.11* 0.19 ± 0.08 0.56 ± 0.07†,# 
Total Carnitine 303.6 ± 33.3 319.3 ± 37.4 223.6 ± 11.7* 196.1 ± 18.9† 
* p<0.05 Vehicle-treated jvs+/- or VPA-treated wild type vs. vehicle-treated wild type; † p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # 
p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
 
Table 5: Liver carnitine content. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and jvs+/- mice were 
treated orally with normal saline or VPA for 14 days. Carnitine was determined using a radioenzymatic method. Units are nmol/g wet tissue. 
Results are presented as mean ± SD. LCA, long-chain-acylcarnitine; SCA, short-chain-acylcarnitine; TAS, total acid soluble carnitine.  
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VPA treatment. The total carnitine content was 16% lower in vehicle-treated jvs+/- 
mice compared to the respective wild type mice. Treatment with VPA was associated 
with a 15% drop in the total carnitine content in jvs+/- mice, but did not affect 
significantly the total carnitine content in wild type mice (Table 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.5 Discussion 
 
Our study shows that jvs+/- mice treated with VPA have impaired hepatic 
mitochondrial β-oxidation and increased hepatic fat accumulation, findings associated 
with increased activities of serum transaminases and alkaline phosphatase, and 
hepatocellular damage. 
In vivo determination of hepatic β-oxidation revealed a decrease in palmitate 
metabolism in VPA-treated jvs+/- mice, which was not the case for VPA-treated wild 
type or vehicle-treated jvs+/- mice. In combination with the liver enzyme elevations, 
these findings suggest that VPA is more toxic in jvs+/- mice than in wild type mice, 
supporting our initial hypothesis that carnitine deficiency is a risk factor for 
hepatotoxicity associated with VPA. VPA is metabolized primarily by conjugation with 
glucuronic acid or carnitine, and to a lesser extent by mitochondrial β-oxidation, 
microsomal ω-oxidation and ω-1-oxidation (Zaccara et al., 1988). Microsomal VPA 
metabolism has been shown to be catalyzed by various cytochrome P450 (CYP) 
isozymes, among them CYP2C9, 2A6 and 2B6 (Kiang et al., 2006). These oxidative 
 Wild type (jvs+/+)  Heterozygous (jvs+/-) 
 vehicle VPA vehicle VPA 
Free Carnitine 276.5 ± 38.0 283.4 ± 21.9 262.7 ± 54.0 194.7 ± 18.7† 
SCA Carnitine 204.0 ± 24.9 204.2 ± 55.0 147.4 ± 18.3 143.9 ± 22.9 
TAS Carnitine 480.4 ± 14.3 487.6 ± 42.0 410.7 ± 35.6* 338.6 ± 12.4†,# 
LCA Carnitine 140.3 ± 4.4 106.9 ± 17.8* 109.5 ± 20.3* 117.7 ± 7.7 
SCA/TAS Carnitine 0.43 ± 0.06 0.41 ± 0.08 0.36 ± 0.06 0.42 ± 0.06 
Total Carnitine 620.7 ± 12.8 594.5 ± 44.2 520.2 ± 31.6* 443.9 ± 26.1†,# 
* p<0.05 Vehicle-treated jvs+/- or VPA-treated wild type vs. vehicle-treated wild type; † p<0.05 VPA-treated jvs+/- vs. VPA-treated wild type; # 
p<0.05 VPA-treated jvs+/- vs. vehicle-treated jvs+/- 
 
Table 6: Muscle carnitine content. The mice were starved overnight before the final experiments, n = 5 for each group. Wild type and jvs+/- mice 
were treated orally with normal saline or VPA for 14 days. Carnitine was determined using a radioenzymatic method. Units are nmol/g wet tissue. 
Results are presented as mean ± SD. LCA, long-chain-acylcarnitine; SCA, short-chain-acylcarnitine; TAS, total acid soluble carnitine.  
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pathways can yield potentially hepatotoxic products, e.g. pentanoate and propionate, 
as well as 4-en-VPA and others. It is conceivable that a reduction in the hepatic 
availability of carnitine in jvs+/- mice can be associated with reduced conjugation of 
VPA, shifting more VPA into the oxidative pathways and possibly leading to hepatic 
toxicity. The observed decrease in the hepatic free carnitine content in vehicle-
treated jvs+/- versus wild type mice and the even more pronounced decrease in the 
hepatic carnitine content of jvs+/- mice treated with VPA support such a mechanism. 
In addition, a reduction in the free carnitine pool is associated with similar changes in 
the CoA pool (Ponchaut et al., 1992b; Krahenbuhl et al., 1995), because these pools 
are connected with each other by the carnitine acyltransferases. A drop in cellular 
CoASH should impair enzymes and/or metabolic pathways using CoASH, for 
instance pyruvate dehydrogenase and β-oxidation of fatty acids. 
If only production and presence of toxic metabolites were responsible for hepatic 
toxicity of VPA, this toxicity could be expected to decrease or even to disappear in 
isolated mitochondria, due to loss of toxic metabolites during the isolation procedure 
(Spaniol et al., 2003). As shown in Table 2, this was clearly not the case in the 
current investigations, suggesting that mitochondrial changes on the gene expression 
and/or structural level are associated with VPA treatment. Earlier studies by 
Hayasaka et al. (Hayasaka et al., 1986) and by Ponchaut et al (Ponchaut et al., 
1992a) have indeed demonstrated that long-term treatment with VPA is associated 
with changes in the composition of cytochrome c oxidase (complex IV), namely a loss 
cytochrome aa3. A reduced activity of complex IV associated with VPA treatment 
explains not only impaired oxidation of succinate and L-glutamate, but also of 
palmitate, as observed in our studies (table 2). On the other hand, the reduced 
activity of mitochondrial β-oxidation, which has been described in other studies 
assessing hepatic toxicity of VPA (Turnbull et al., 1983; Baldwin et al., 1996), can be 
explained most probably by interactions of toxic metabolites with enzymes involved in 
β-oxidation (Ito et al., 1990; Baldwin et al., 1996). 
A comparison of palmitate oxidation in vivo and in vitro reveals that in vivo, β-
oxidation was impaired only in VPA-treated jvs+/- mice, whereas in vitro, palmitate 
oxidation was reduced also in liver mitochondria from VPA-treated wild-type mice. It 
has to be taken into account that in vivo only a tracer dose was administered 
whereas saturating concentrations of palmitate were used in the in vitro studies. 
Furthermore, palmitate could have been metabolized in vivo to a minor part also by 
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extrahepatic tissues, rendering small differences in hepatic activity of β-oxidation 
more difficult to detect. Finally, it can be argued that reduced in vivo β-oxidation of 
palmitate is primarily due to hepatic carnitine deficiency, which was most accentuated 
in livers from VPA-treated jvs+/- mice (Table 5). 
The fact that the skeletal muscle carnitine pools were much less affected by OCTN2 
activity and by VPA administration than the hepatic carnitine pools may serve as one 
possible explanation for reduced toxicity of VPA in skeletal muscle. In addition, the 
CYPs involved in the metabolism of VPA have the highest expression in liver 
(Gonzalez, 1992), and not in skeletal muscle. Nevertheless, VPA fat accumulation 
and morphological mitochondrial abnormalities have been described both in children 
and in rats with long-term VPA treatment (Melegh and Trombitas, 1997). 
Body carnitine homeostasis was affected by both activity of OCTN2 (jvs+/- vs. wild 
type mice) and treatment with VPA. As expected, jvs+/- mice had clearly reduced 
plasma and liver carnitine pools compared to wild type mice, demonstrating the 
importance of renal carnitine reabsorption associated with OCTN2. Interestingly, the 
effect of partial loss of OCTN2 activity was less accentuated for skeletal muscle than 
for liver, a finding which can at least partially be explained by the resistance of the 
plasmalemmal membrane for transport of carnitine (Rebouche and Engel, 1984). The 
effect of VPA treatment on the carnitine plasma and tissue stores was much more 
dramatic in JVS+/- than in wild type mice, leading to additional and substantial losses 
in the plasma and tissue carnitine pools. As shown in Table 4, this is a consequence 
of a massive increase in the renal excretion of carnitine and of acylcarnitines, in this 
case most probably valproylcarnitine (Muro et al., 1995). Although precise data are 
lacking, the increase in renal carnitine excretion can most probably be explained by 
the competition between valproylcarnitine (and possible other acylcarnitines) with 
carnitine for proximal tubular reabsorption by OCTN2 (Okamura et al., 2006). 
In conclusion, hepatic toxicity of VPA is more pronounced in JVS+/- mice than in 
corresponding wild type mice. Carnitine deficiency can therefore be considered to be 
a risk factor for VPA-associated hepatotoxicity, showing the importance of a sufficient 
hepatic carnitine pool in patients treated with this drug. 
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8.1 Abstract 
 
Drug-induced changes in the activity of drug-metabolizing enzymes, e.g. cytochrome 
P450 (CYP), are an important cause of drug-drug interactions, possibly resulting in 
loss of efficacy. Prediction of such changes is therefore a prerequisite of early drug 
development. Since availability and quality of fresh human hepatocytes is 
problematic, hepatocyte cell lines may serve as an alternative. In this study, we have 
investigated expression and induction of several CYP isozymes and the human 
pregnane X receptor (hPXR) in the immortalized human hepatocyte cell line 
hHepLT5 and in HepG2 cells used as a comparator. hPXR, CYP1A2 and CYP3A4 
expression was observed in HepG2 as well as in hHepLT5. CYP2D6 and CYP2C9 
were detectable only in HepG2 but not in hHepLT5, and CYP2C19 expression could 
not be found in both cell lines. Treatment with 50 µM omeprazole did not affect 
CYP1A2 mRNA induction in both cells. Treatment with 25 µM rifampicin was 
associated with a 3.4-fold increase in CYP3A4 mRNA in HepG2 but no increase in 
hHepLT5 cells. In conclusion, hHepLT5 cells contain the hPXR and the CYP 
isozymes 1A2 and 3A4 but could not be induced by prototypical incucers compared 
to HepG2 cells. 
 
8.2 Introduction 
 
Drug-drug and food-drug interactions caused by changes in the expression of 
cytochrome P450 (CYP) genes play an important role in the occurrence adverse drug 
reactions and/or loss of therapeutic effect of drugs (Li et al., 1997b; Michalets, 1998). 
Therefore, it is of great interest to investigate the inductive, but also the inhibitory 
potential of new chemical entities to predict possible changes in drug metabolism. 
CYPs, representing monooxygenases containing a heme group, are the most 
important group of enzymes involved in phase I metabolism of xenobiotics, primarily 
in the liver (Guengerich, 1990). The activity of most CYPs can be regulated by 
induction and/or inhibition by specific drugs, possibly affecting the metabolism of 
other drugs (Tanaka and Misawa, 1998; Jones et al., 2000; Lin and Lu, 2001) or 
even their own metabolism, e.g. by autoinduction (Strolin Benedetti et al., 1990). 
The pregnane X receptor (PXR), an orphan nuclear receptor, is one of the key 
transcriptional regulators of cytochrome P450 CYP3A monooxygenases and other 
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drug metabolizing enzymes and transporters. PXR is activated by a variety of 
endogenous (e.g. steroids and bile acids), and exogenous compounds (e.g. 
rifampicin, phenytoin and hyperforin) through direct interaction with these 
compounds. PXR activation assays can be used to predict the induction of CYP3A 
gene expression by drug candidates and therefore to predict drug-drug interactions 
(Lehmann et al., 1998; Goodwin et al., 2002; Kliewer et al., 2002).  
Primary human hepatocytes are considered as the gold standard and as a common 
model for the in vitro assessment of cytochrome P450 manipulation by new drug 
candidates (LeCluyse, 2001), and there are several studies using primary human 
hepatocytes for pharmacological and toxicological investigations (Donato et al., 1995; 
Guillouzo et al., 1997; Kern et al., 1997; Li et al., 1997a). Nevertheless, there are 
several disadvantages occurring with this screening system. For instance, primary 
cultures of human hepatocytes lose the expression of CYPs during a short culture 
period, they show interindividual variability and different quality, and the availability is 
limited. A possible alternative is the use of HepG2 or LS180 cells, which are used 
widely as in vitro screening systems. However, it is known that the expression of 
most CYPs in HepG2 cells is very low or even lacking and can change during culture 
(Rodriguez-Antona et al., 2002; Wilkening and Bader, 2003; Wilkening et al., 2003; 
Westerink and Schoonen, 2007).  
In order to circumvent some of these drawbacks, we investigated immortalized 
human hepatocytes, a cell line produced in our laboratory. The cells were 
characterized by studying the mRNA expression and activity of their CYPs and by 
studying CYP induction. 
 
 
8.3 Materials and Methods 
 
Reagents 
Dulbecco’s Modified Eagle Medium (DMEM), phosphate buffered saline (PBS), fetal 
bovine serum (FBS), penicillin/streptomycin, GlutaMAX, HEPES and non essential 
amino acids (NEAA) for the culture of the cell lines were purchased from Invitrogen 
(Basel, Switzerland). Williams E Medium (WEM) was from Cambrex (Verviers, 
Belgium). Rifampicin (RIF), omeprazole (OME), insulin, dimethyl sulfoxide (DMSO) 
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and dexamethason were obtained from Sigma Aldrich (Buchs, Switzerland). All 
chemicals used in this study were of the highest purity available. 
 
Hepatocyte cell lines and cell culture conditions 
HepG2 cells (hepatocellular carcinoma cell line) were kindly provided by Professor 
Dietrich von Schweinitz (University Hospital Basel, Switzerland) and were used 
between passage 4 – 8.  
The hHepLT5 cell line was generated in our laboratory by transducing the simian 
virus 40 large T antigen (SV40TAg) gene into primary human hepatocytes (Becton 
Dickinson, Woburn, US) using a HIV-derived lentiviral vector as described by Salmon 
et al. (Salmon et al., 2000). Clones (named hHepLT) were generated by single cell 
cloning using serial dilution and selected according to their morphological features 
and culture properties. 
hHepLT5 cells were cultured in Biocoat collagen I-coated plates (BD biosciences, 
Allschwil, Switzerland) in Williams E Medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum, 10 mmol/l HEPES buffer, pH 7.4, 2 mmol/l GlutaMAX, 
penicillin/streptomycin 100 U/ml, insulin 20 mU/ml and dexamethason 100 nmol/l.  
For the investigation of CYP1A2 enzyme activity, both cell lines were plated on 24 
well plates at density of 2x105 cells per well. For mRNA expression studies, the cells 
were used after they reached confluence.  
 
Total RNA extraction and cDNA synthesis 
At the end of the culture period, medium was removed and total RNA was isolated 
from cultured cells using the RNeasy Mini Kit from Qiagen (Hombrechtikon, 
Switzerland) and quantified with a Nano Drop ND-1000 spectrophotometer (Witec 
AG, Littau, Switzerland). The absorption ratio at 260 nm/280 nm (Nano Drop ND-
1000 spectrophotometer) was in the range of 1.8 – 2.0. After DNase I digestion 
(Invitrogen, Basel, Switzerland), synthesis of cDNA was carried out using 1 – 5 µg 
total RNA which was reversed transcribed by Superscript II Reverse Transcriptase 
(Invitrogen, Basel, Switzerland) according to the manufacturer’s protocol using 
random hexamer primers.  
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Real time polymerase chain reaction (TaqMan assay) 
TaqMan analysis was performed using 10 ng of cDNA in a total volume of 10 µl per 
TaqMan reaction as a template for quantitative real time PCR analysis on a 7900HT 
Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). Primers 
and probes were designed according to the guidelines of Applied Biosystems with 
Primer Express 2.0 software (Applied Biosystems) and were synthesized by 
Eurogentec (Seraing, Belgium). The probes consisted of an oligonucleotide with a 5’ 
reporter dye (FAM) and a 3’ quencher dye (TAMRA). Primers and probes for all 
isoforms were used at concentrations of 900 nm and 200 nm, respectively. 
Sequences of primers and probes are listed in Table 1. TaqMan Universal PCR 
Mastermix was purchased from Eurogentec (Seraing, Belgium). Cycling conditions 
were 10 min at 95°C for initial denaturation and ac tivation of the DNA polymerase, 
followed by 40 cycles of 15 s at 95°C for denaturat ion and 1 min at 60°C for 
combined annealing and primer extension. All samples were run in triplicates and 
were quantified using the ∆∆Ct method. The threshold cycles (Ct) of the genes of 
interest in all samples were normalized to these of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Ctgene of interest – CtGAPDH = 
∆Ct). For induction experiments, the effect of the compounds tested on the genes of 
interest were normalized to the dimethyl sulfoxide (DMSO) control sample 
(∆Ctcompound – ∆CtDMSO = ∆∆Ct). Fold changes in the expression of the genes of 
interest were calculated by taking 2 to the power of the ∆∆Ct value (2- ∆∆Ct) as 
described in the user bulletin of Applied Biosystems.   
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primer sense Sequence (5’? 3’) GenBank 
   accession number 
GAPDH  Forward   GGTGAAGGTCGGAGTCAACG   X01677 
  Probe   CGCCTGGTCACCAGGGCTGC 
  Reverse   ACCATGTAGTTGAGGTCAATGAAGG    
hPXR  Forward   GGCCACTGGCTATCACTTCAA   AF061056   
   Probe   AGCCCTTGCATCCTTCACATGTCATGA 
   Reverse   GTTTCATGGCCCTCCTGAAA 
CYP1A2   Forward   TGTTCAAGCACAGCAAGAAGG   AF182274 
   Probe   CTAGAGCCAGCGGCAACCTCATCCCA 
   Reverse   TGCTCCAAAGACGTCATTGAC 
CYP2C19   Forward   GAACACCAAGAATCGATGGACA   NM_000769 
   Probe   TAATCACTGCAGCTGACTTACTTGGAGCTGGG 
   Reverse   TCAGCAGGAGAAGGAGAGCATA 
CYP2C9   Forward   GACATGAACAACCCTCAGGACTTT   NM_000771 
   Probe   AAAACACTGCAGTTGACTTGTTTGGAGC 
   Reverse   TGCTTGTCGTCTCTGTCCCA 
CYP2D6   Forward   CCTACGCTTCCAAAAGGCTTT   NM_000106 
   Probe   CAGCTGGATGAGCTGCTAACTGAGCACA 
   Reverse   AGAGAACAGGTCAGCCACCACT 
CYP3A4   Forward    GATTGACTCTCAGAATTCAAAAGAAACTGA   AF182273 
   Probe    AGGAGAGAACACTGCTCGTGGTTTCACAG 
   Reverse    GGTGAGTGGCCAGTTCATACATAATG 
 
Table 1: Sequences of gene specific primers and probes used for real time polymerase chain reaction. 
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Statistical analysis 
All analyses were performed in triplicate. The results are presented as mean ± SD 
from four separate experiments. Significant differences between groups were 
determined by ANOVA/Bonferroni multiple comparison post hoc test. P values <0.05 
were considered to be significant. 
 
8.4 Results 
 
The aims of this study were to prepare a cell line of immortalized human hepatocytes 
and to characterize these cells regarding the expression pattern and inducibility of 
different CYP isozymes and of the human pregnane X receptor (hPXR). The results 
from these cell lines were compared to those obtained in HepG2 cells. 
 
Immortalization of human hepatocytes 
Transduction of human hepatocytes with the simian virus 40 large T antigen 
(SV40TAg) gene (Salmon et al., 2000) yielded several clones, which were selected 
according to morphology and culture properties. The clone hHepLT5 showed 
comparable morphological characteristics as primary cultured hepatocytes (see 
Figure 1) and was easy to culture. This clone was therefore used for the current 
studies. 
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Figure 1: Morphology of hHepLT5 cells. The hHepLT cell lines were generated by transducing the 
simian virus 40 large T antigen (SV40TAg) gene into primary human hepatocytes using a HIV-derived 
lentiviral vector. Clones were obtained by single cell cloning using serial dilution as described in 
Methods. The hHepLT5 cell line (Figure 1B) shows morphological features close to human 
hepatocytes (Figure 1A) and was therefore used for CYP characterization. 
 
 
mRNA expression of hPXR 
As shown in Figure 2, hPXR mRNA was expressed in HepG2 and in hHepLT5. The 
hPXR mRNA levels in hHepLT5 cells contained approximately 5 times less hPXR 
mRNA than HepG2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure2: mRNA expression of hPXR. Expression of hPXR mRNA could be detected in HepG2 and 
hHepLT5 cells. The hPXR mRNA levels were significantly lower in hHepLT5 cells vs. HepG2 cells. 
***P < 0.001 vs. HepG2 cells.  
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Gene expression of CYP1A2, CYP2D6, CYP3A4, CYP2C9 and CYP2C19 
To compare the CYP isozyme mRNA expression levels in the immortalized human 
hepatocytes cell line, the mRNA expression was normalized to that of untreated 
HepG2 cells. As shown in Figure 3, CYP1A2 was expressed in both cell lines. In 
comparison to HepG2 cells, the mRNA expression levels were elevated 2.7-fold in 
hHepLT5 cells. CYP3A4 mRNA expression could also be detected in HepG2 and in 
hHepLT5 cells, whereas the mRNA levels were approximately 2-fold lower in 
hHepLT5, compared to HepG2 cells. The CYP2D6 and CYP2C9 mRNA expression 
was observed in HepG2, but not in hHepLT5 cells. CYP2C19 mRNA expression was 
not detectable in HepG2 and in hHepLT5 cells (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: mRNA expression of several CYP isozymes. The immortalized human hepatocyte cell line 
hHepLT5 revealed mRNA expression of CYP1A2 and CYP3A4, but not of CYP2D6 and CYP2C9. *** 
P < 0.001 vs. HepG2 cells. 
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Inducibility of CYP isozymes 
Cells were incubated with medium containing 0.1% DMSO as vehicle control, with 
rifampicin (10 and 25 µM) for the induction of CYP3A4, CYP2C19 and CYP2C9, or 
with omperazole (25 and 50 µM) for the induction of CYP1A2 for 72 hours. After 
treatment with rifampicin, CYP2C9, CYP2C19 and CYP2D6 were not induced in both 
cell lines (results not shown). As shown in Figure 4, HepG2 cells showed a 
concentration-dependent significant increase in CYP3A4 mRNA levels in the cells 
treated with rifampicin as compared to the untreated group. CYP3A4 mRNA levels in 
HepG2 were increased 1.6-fold and 3.4-fold after treatment with 10 µM and 25 µM 
rifampicin, respectively. In hHepLT5 cells no CYP3A4 mRNA induction could be 
observed after treatment with 10 µM and 25 µM rifampicin. Furthermore, the CYP1A2 
mRNA levels were not affected by treatment with omeprazole in HepG2 and in 
hHepLT5 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: mRNA expression of CYP3A4 after induction with rifampicin. Both cell lines were treated for 
72 hours with medium only, or with rifampicin or omeprazole in different concentrations. The mRNA 
expression is shown relative to the respective control incubations (DMSO 0.1%). Results are 
presented as fold change compared to DMSO 0.1%. OME= omeprazole, RIF = rifampicin. * P < 0.05, 
** P < 0.01, *** P < 0.001 vs. DMSO 0.1%. 
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8.5 Discussion 
 
In the current study, we have investigated the expression and the inducibility of 
several CYP isozymes in a hepatocellular carcinoma cell line and immortalized 
human hepatocytes. Since CYP3A4, 2D6, 1A2 and 2C are the main human CYP 
isozymes associated with drug metabolism, information about inhibitory and/or 
inducing characteristics of chemical substances may be helpful for the prediction of 
drug-drug interactions (Michalets, 1998). 
CYP1A2 is responsible for about 10 to 15% of the total CYP content of human liver 
and is the major CYP isozyme involved in the metabolism of important drugs, e.g. 
imipramine, propranolol, clozapine, olanzapine, theophylline and caffeine (Brosen, 
1995). mRNA expression of CYP1A2 could be detected in both cell lines investigated 
(Figure 2). In comparison to HepG2 cells, the mRNA expression levels were 
significantly higher in hHepLT5 cells. These results are in accordance with previous 
reports, where mRNA levels of CYP1A2 in HepG2 cells were very low (Rodriguez-
Antona et al., 2002; Wilkening et al., 2003; Westerink and Schoonen, 2007). After 
induction with omeprazole, which has been shown to be an efficient CYP1A2 inducer 
(Diaz et al., 1990; Daujat et al., 1992; Curi-Pedrosa et al., 1994), CYP1A2 induction 
could not be detected in both cell lines investigated.  
CYP3A4 is the predominant cytochrome P450 enzyme found in human liver, 
accounting for up to 30% of total hepatic CYP protein content (Shimada et al., 1994). 
CYP3A4 is known to metabolize a large variety of xenobiotics (among them 
amiodarone, lipophilic HMG-CoA reductase inhibitors, cyclosporine, tacrolimus and 
sirolimus, and various anticancer drugs) and endogenous substances, such as 
steroids (Brian et al., 1990; Araya and Wikvall, 1999). The results of our studies 
indicate that CYP3A4 mRNA expression is lower in hHepLT5 cells compared to 
HepG2. Rifampicin, a known inducer of CYP3A4 and other CYP isozymes (Kern et 
al., 1997; Rae et al., 2001; Raucy et al., 2002), was able to induce CYP3A4 mRNA 
levels in a concentration-depending manner in HepG2 cells, but not in hHepLT5 cells. 
CYP3A4 mRNA induction correlates with mRNA expression of hPXR, which showed 
a high expression in HepG2 cells, but a low or even lacking expression in hHepLT5 
cells. In agreement with CYP3A4 mRNA induction, also CYP3A4 activity was induced 
by rifampicin in HepG2.  
The CYP2C subfamily is also important for drug metabolism, accounting for 
approximately 18% of the CYP protein content in human liver and for approximately 
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20% of the CYP-mediated metabolism of drugs (Rendic and Di Carlo, 1997). The 
CYP2C9 isozyme is, among others, responsible for the metabolism of warfarin, 
phenytoin and various non-steroidal anti-inflammatory agents (Rettie et al., 1992; 
Bajpai et al., 1996; Hamman et al., 1997; Miners and Birkett, 1998). CYP2C19 plays 
a role in the metabolism of phenytoin (Levy, 1995), and is involved in the metabolism 
of omeprazole and diazepam (Andersson et al., 1993; Jung et al., 1997). In our 
study, CYP2C9 mRNA was detectable in HepG2, but not in hHepLT5 cells. In 
comparison, CYP2C19 mRNA expression was neither detectable in HepG2 nor in 
hHepLT5 cells. As shown in other studies, the expression of CYP2C9 and 2C19 is 
generally low or even inexistent in HepG2 cells and can change during culture (Ogg 
et al., 1999; Pourreyron et al., 2003; Plant, 2004; Westerink and Schoonen, 2007). 
As discussed above, our results show that the hPXR activator rifampicin is able to 
induce CYP3A4 in HepG2 cells. On the other hand, rifampicin was not able to induce 
CYP2C9 despite the presence of hPXR. This finding differs from other studies with 
cultured hepatocytes (Gerbal-Chaloin et al., 2001; Chen et al., 2004). At least in 
HepG2 cells, hPXR expression is therefore not sufficient for CYP2C9 mRNA 
expression by rifampicin. Regarding CYP2C9 and 2C19, HepG2 cells can be used to 
test drug metabolism, but are not suitable to investigate enzyme induction. 
CYP2D6 is responsible for the metabolism of many psychotherapeutic agents (e.g. 
amitriptyline, haloperidol, risperidone) and also of beta-blockers (e.g. metoprolol). 
Expression of CYP2D6 mRNA could only be detected in HepG2, but not in hHepLT5 
cells. CYP2D6 appears not to be inducible by the hPXR inducer rifampicin, as 
described in other studies (Li et al., 1997b; Edwards et al., 2003; Glaeser et al., 
2005). Similar to our statement regarding CYP2C9 and 2C19, only HepG2 cells could 
possibly be used to test the metabolism of drugs CYP2D6. 
In conclusion, hHepLT5 cells contain the CYP isozymes CYP1A2 and 3A4 which are 
involved in the metabolism of a variety of drugs. The immortalized human 
hepatocytes cell line hHepLT5 appear therefore to be a suitable alternative for 
primary human hepatocytes for studying at least certain pharmacological and 
toxicological features of new drug entities. 
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9.1 Abstract 
 
Extracts of cimicifuga racemosa are used frequently for menopausal complaints. 
Cimicifuga is well tolerated, but can occasionally cause liver injury. To assess 
hepatotoxicity of cimicifuga in more detail, ethanolic cimicifuga racemosa extract was 
administered orally to rats and liver sections were analyzed by electron microscopy. 
Tests for cytotoxicity, mitochondrial toxicity and apoptosis/necrosis were performed 
using HepG2 cells. Mitochondrial toxicity was studied using isolated rat liver 
mitochondria. Microvesicular steatosis was found in rats treated with >500µg/kg body 
weight cimicifuga extract. In vitro, cytotoxicity was apparent at concentrations 
≥75µg/mL and mitochondrial β-oxidation was impaired at concentrations ≥10µg/mL. 
The mitochondrial membrane potential was decreased at concentrations ≥100µg/mL 
and oxidative phosphorylation was impaired at concentrations ≥300µg/mL. The 
mechanism of cell death was predominantly apoptosis. Cimicifuga racemosa exerts 
toxicity in vivo and in vitro, eventually resulting in apoptotic cell death. The results are 
compatible with idiosyncratic hepatotoxicity as observed in patients treated with 
cimicifuga extracts. 
 
Key words: Cimicifuga racemosa, hepatotoxicity, mitochondria, apoptosis, HepG2 
 
9.2 Introduction 
 
Hormone replacement therapy (HRT) has been considered to be the standard 
treatment of menopausal disturbances. The association of HRT with breast and 
uterus cancer (Rossouw et al., 2002) and the desire of many women for a “natural 
treatment” were the main reasons why alternative therapies became increasingly 
popular. Especially extracts of the plant cimicifuga racemosa are currently used for 
this indication. Cimicifuga racemosa, also called actaea racemosa or black cohosh, is 
a member of the buttercup family (ranunculaceae), and originates from the Eastern 
part of the United States and Canada. Traditionally, the rhizome was used by North 
American Indians for joint aches, myalgias, neuralgias and rheumatic disorders, but 
also for menopausal complaints and pain during labour. Nowadays, ethanolic or 
isopropanolic extracts of cimicifuga racemosa are most commonly used for the 
symptomatic treatment of menopausal disorders and of the premenstrual syndrome 
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(McKenna et al., 2001; Frei-Kleiner et al., 2005; Nappi et al., 2005; Uebelhack et al., 
2006), although not all studies have shown a better effect than placebo (Pockaj et al., 
2006). 
Data from clinical studies and spontaneous reporting programs suggest that adverse 
events associated with cimicifuga racemosa are rare, generally mild and reversible. 
Gastrointestinal upset and rashes were the most common adverse events reported 
(Dog et al., 2003; Huntley and Ernst, 2003). In mostly uncontrolled clinical trials and 
post-marketing studies including more than 2,800 patients, adverse events had an 
incidence of 5.4%. Of the reported adverse events, 97% were minor or mild, none of 
them resulting in discontinuation of the therapy. When higher doses than those 
recommended are used, however, cimicifuga racemosa can cause dizziness, 
headaches, nausea, and vomiting (Dog et al., 2003). In their review, which includes 
all post-marketing programs of cimicifuga extracts, Huntley et al. also described 
patients with hepatic adverse events (Huntley and Ernst, 2003). They reported one 
case with hepatic failure, three cases with hepatitis and three cases with increased 
liver enzymes. In addition, several case reports have been published about patients 
developing acute hepatitis (Whiting et al., 2002; Cohen et al., 2004) or fulminant liver 
failure (Lontos et al., 2003; Levitsky et al., 2005; Lynch et al., 2006) while being 
treated with cimicifuga extracts. The European Medicines Agency (EMEA) recently 
assessed the case reports of hepatotoxicity associated with ingestion of cimicifuga 
racemosa root extracts (EMEA/HMPC/88766/2006). The conclusion was that all the 
cases reported in the literature and all pharmacovigilance reports are poorly 
documented and that these adverse events should be interpreted as a signal. 
Systematic investigations and careful assessment of the present and possibly future 
cases by the marketing authorization holders is appreciated by the EMEA. 
Since an association of hepatotoxicity with cimicifuga appears to be possible, we 
decided to investigate the potential for hepatotoxicity of cimicifuga extracts in 
experimental animals in vivo, in hepatocyte cultures and in isolated liver 
mitochondria. 
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9.3 Material and Methods 
Chemicals 
The cimicifuga extract was obtained from Max Zeller Söhne AG (Romanshorn, 
Switzerland, batch number V2009). The extraction solvent was 60% ethanol (v:v) 
with a ratio of native herbal drug to drug preparation of 4.5-8.5:1 (w:w), depending on 
the content of triterpene glycosides (≥6%). Solutions of the extract were made by 
dissolving the extract in DMSO. Caffeic acid and ferulic acid were purchased from 
Fluka (Buchs, Switzerland) and cimiracemoside A was from ChromaDex (Santa Ana, 
CA, USA). JC-1 and propidium iodide were from Molecular Probes (Eugene, OR, 
USA); Z-Val-Ala-Asp-fluoromethylketone (zVAD-fmk) and Z-Phe-Ala-fluoromethyl-
ketone (zFA-fmk) were from Enzyme Systems Products (Livermore, CA, USA). Alexa 
Fluor 633 labelled annexin V was a generous gift of Dr. Felix Bachmann, Aponetics 
Ltd. (Witterswil, Switzerland). [1-14C] palmitic acid was obtained from Amersham 
Pharmacia Biotech (Dübendorf, Switzerland). The scintillation cocktail was from 
Perkin Elmer (Boston, MA, USA). The Cy3TM conjugated anti-sheep IgG was 
purchased from Jackson Laboratories (West Grove, PA, USA). All other chemicals 
were from Sigma (Buchs, Switzerland) and of highest quality available when not 
otherwise stated. 
 
In vivo hepatotoxicity of cimicifuga extract 
Groups of 5 female Wistar rats were fed each with daily doses of 1, 10, 100, 300 or 
1000mg/kg body weight of cimicifuga racemosa extract. The extract was 
administered as a suspension in a solution of Arabic gum in water by means of 
esophageal gavage over a period of 21 days. After anesthesia and decapitation, the 
livers of the animals were perfused for fixation, tissue blocks were excised and 
prepared for electron microscopy as described previously in detail (Spornitz et al., 
1999). The study protocol had been accepted by the Animal Ethics Committee of the 
Canton of Basel. 
 
Cell culture 
The human hepatocarcinoma cell line HepG2 was kindly provided by Dr. Dietrich von 
Schweinitz (Department of Pediatric Surgery, Children’s Hospital, University of 
Basel). The cell line was grown in RPMI 1640 medium supplemented with 
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GlutaMAXTM-I, 25mM HEPES, 10% (v/v) heat-inactivated fetal bovine serum and 
100U/mL penicillin/streptomycin (all from Gibco, Paisley, UK). Culture conditions 
were 5%CO2 and 95% air atmosphere at 37°C. Experiments were p erformed when 
the cells had reached a confluence of about 80%. 
 
Cytotoxicity tests 
To examine cell viability and reductive activity, the MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] assay was performed in HepG2 as described 
originally by Mosmann (Mosmann, 1983), but including an additional washing step 
(Bruggisser et al., 2002). 
In addition, the sulforhodamine B (SRB) test was performed according to the protocol 
of Skehan (Skehan et al., 1990) and the lactate dehydrogenase (LDH) assay 
according to Vassault (Vassault, 1983). 
 
Isolation of rat liver mitochondria 
Male Sprague Dawley rats (Charles River, Les Onins, France) were anesthetized 
with carbon dioxide and killed by decapitation. Liver mitochondria were isolated by 
differential centrifugation according to the method of Hoppel et al (Hoppel et al., 
1979). The mitochondrial protein content was determined using the biuret method 
with bovine serum albumin as a standard (Gornall, 1949). 
 
In vitro mitochondrial β-oxidation 
Beta-oxidation with freshly isolated liver mitochondria was assessed as the formation 
of 14C-acid-soluble β-oxidation products from [1-14C] palmitic acid in the presence of 
the cimicifuga extracts. Experiments were performed as described initially by 
Freneaux et al. (Freneaux et al., 1988) with the modifications described by Spaniol et 
al (Spaniol et al., 2001a). 
 
Oxygen consumption 
Polarographic monitoring of oxygen consumption in rat liver mitochondria was carried 
out in a 1mL chamber equipped with a Clark-type oxygen electrode (Yellow Springs 
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Instruments, Yellow Springs, OH, USA) at 30°C as de scribed previously (Krahenbuhl 
et al., 1991). Subsequent experiments with the F1F0-ATPase inhibitor oligomycin 
(5µg/mL) were performed to check for uncoupling of oxidative phosphorylation 
(Kaufmann et al., 2005). 
 
Mitochondrial membrane potential 
To determine the mitochondrial membrane potential, the dye JC-1 (5,5',6,6'-
tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide) was used accor-
ding to the protocol of Molecular Probes. Cells were incubated with different 
concentrations of cimicifuga extract for 24 hours. After the addition of JC-1 and 10 
minutes of incubation, cell fluorescence was determined by flow cytometry 
(FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA) (Kaufmann et al., 2006). 
 
Determination of intracellular GSH and GSSG content 
In order to assess the redox status of the treated HepG2 cells and possible formation 
of reactive metabolites, determination of GSH (glutathione) and GSSG (oxidized 
glutathione) was performed using the enzymatic recycling assay of Tietze (Tietze, 
1969), with the modifications described by Griffith et al. (Griffith, 1980). 
 
Apoptosis / Necrosis 
Discrimination between apoptosis and necrosis was done with the AnnexinV/ 
propidium iodide stain. HepG2 cells were incubated for 24 hours with the extract. 
After trypsinization and centrifugation, cells were resuspended in RPMI medium 
(adjusted to 2.5mM calcium), stained with Alexa Fluor 633 labelled annexin V and 
propidium iodide (final concentration 1µg/mL) and analyzed by FACS (FACSCalibur, 
Becton Dickinson) (Kaufmann et al., 2005). 
 
ATP determination 
The ATP content of HepG2 cells treated with cimicifuga extract was determined with 
the luciferin/luciferase method using the ATP bioluminescence assay kit from Sigma 
as described previously (Kaufmann et al., 2005). 
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Hoechst staining 
HepG2 cells were incubated with cimicifuga extract for 24 hours, stained with 0.1mM 
Hoechst 33342 dye and visualized with an inverted fluorescent microscope (Olympus 
IX50, Hamburg, Germany). 
 
Cytochrome c staining 
HepG2 cells (105 cells) were seeded into a 8-well chamber slide (Nunc Labtek, 
Naperville, IL, USA) and cultured for two days. Subsequently, cells were incubated 
for 24 hours with cimicifuga extracts as described in the result section. The cells were 
fixed in 4% paraformaldehyde and analyzed for cytochrome c as described 
previously (Kaufmann et al., 2005). 
 
Statistical methods 
Data represent mean ± SEM of at least 4 replicates. Statistical analysis of differences 
between control incubations and incubations with cimicifuga extract was performed 
using analysis of variance (ANOVA) and Dunnett's multiple comparison test as 
posthoc test to localize differences obtained by ANOVA. A p-value <0.05 was 
considered to be statistically significant. 
 
 
9.4 Results 
Our aims were first to find out whether cimicifuga is hepatotoxic in vivo in rats and 
second, if in vivo hepatotoxicity could be demonstrated, to find out its mechanisms by 
in vitro investigations. There were no differences in food consumption and body 
weight increase between the rats treated with cimifuga extract and the respective 
control rats (data not shown). Rats treated with 10mg per kg body weight showed a 
slight increase in the volume of hepatocellular mitochondria (mitochondrial swelling) 
and an enlargement of bile canaliculi (data not shown). Rats fed with 100 or 
300mg/kg body weight showed more marked mitochondrial swelling and alterations 
in mitochondrial morphology such as vacuoles in the matrix (data not shown). Rats 
treated with 1000mg/kg body weight developed microvesicular steatosis of the 
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hepatocytes (see Figure 1), glycogen depletion and fragmentation of the rough 
endoplasmic reticulum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Semi-thin section of a liver form a rat treated with 1000 mg/kg body weight of cimicifuga 
extract for 21 days. The majority of the intracellular vesicles are small lipid droplets, which are located 
in the cytoplasm of the hepatocytes and do not displace the nuclei, signs typical for microvesicular 
steatosis. The sections have been stained with paraphenylene diamine (PPD) as described in 
methods. 
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Since microvesicular steatosis usually reflects a mitochondrial damage and can be 
associated with cytotoxicity (Fromenty and Pessayre, 1995; Mahler et al., 1997), the 
MTT test was carried out on HepG2 cells. As shown in Figure 2, cimicifuga extract 
displayed a concentration-dependent toxicity starting at 75µg/mL. Cytotoxicity of 
cimicifuga could be confirmed using the LDH and the sulforhodamine B tests (data 
not shown). In contrast, specific components of the cimicifuga extract, namely caffeic 
acid, ferulic acid or cimiracemoside A, which were investigated at concentrations 
calculated to be equivalent to those in the extract, were not cytotoxic (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Reductive capacity and integrity of HepG2 cells investigated using the MTT test after 
incubation with cimicifuga extracts for 24 hours. In intact cells, MTT is metabolically converted to its 
blue formazan form, whose absorption can be measured at 550 nm, which is presented here. 
Cytotoxicity is detectable beginning at a concentration of 75 µg/mL of cimicifuga extract. Results are 
expressed as mean ± SEM of 10 determinations. *P < 0.05, **p < 0.01 vs. control values. 
 
 
Microvesicular steatosis and a signal in the MTT test were compatible with 
mitochondrial toxicity associated with cimicifuga extract. The mitochondrial 
membrane potential was therefore determined in HepG2 cells treated with cimicifuga 
extract using JC-1 as a marker (Kaufmann et al., 2006). These experiments revealed 
a dose-dependent decrease in the membrane potential, starting at a concentration of 
100µg/mL (see Figure 3). 
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Figure 3: Mitochondrial membrane potential in HepG2 cells incubated with cimicifuga extract. Cells 
were incubated with cimicifuga extract for 24 hours. After this incubation, JC-1 was added (final 
concentration 7.5µM), and cell fluorescence was analyzed using a cell sorter after an incubation of 10 
minutes (Kaufmann et al., 2006). The mitochondrial membrane potential starts to drop at a 
concentration of 100 µg/mL cimicifuga extract, corresponding well with the MTT test shown in Figure 
2. Results are expressed as the percentage of the membrane potential compared to control values, 
which was set at 100%. Results are presented as mean ± SEM of 3 determinations. *P < 0.05 vs. 
control values. 
 
 
 
In order to find out the reasons for the observed decrease in the mitochondrial 
membrane potential, specific mitochondrial functions were studied using freshly 
isolated rat liver mitochondria. The investigation of palmitate metabolism revealed 
that cimicifuga racemosa inhibited mitochondrial β-oxidation in a dose-dependent 
fashion, starting at a concentration of 10µg/mL (Figure 4). At a concentration of 
500µg/mL, the residual activity was only 8.5%. 
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Figure 4: Activity of the β-oxidation pathway of isolated rat liver mitochondria in the presence of 
cimicifuga extract. Beta-oxidation was determined as the formation of ketone bodies using [1-
14C]palmitate as a substrate. Cimicifuga extract shows a dose-dependent toxicity starting at a 
concentration of 10µg/mL. Results are expressed as mean ± SEM of 3 determinations. *P < 0.05, **p 
< 0.01 vs. control values. 
 
 
 
Oxidative phosphorylation is another important metabolic process in mitochondria, 
which is sensitive to toxicants (Waldhauser et al., 2006). As shown in Table 1, state 3 
oxidation rates in the presence of L-glutamate were decreased by 20% starting at a 
concentration of 300 µg/mL of the extract, whereas state 4 oxidation rates were 
increased by 53% or 132% at 300 or 500µg/mL, respectively. In contrast, 
cimiracemoside A did affect neither state 3, nor state 4 oxidation rates (Table 1). In 
order to proof uncoupling of oxidative phosphorylation (as suggested by increased 
state 4 oxidation rates), state 4u was induced by the addition of oligomycin, an 
inhibitor of F1F0-ATPase. As shown in Figure 5, 500µg/mL cimicifuga extract led to a 
significant increase in state 4u oxygen consumption, similar to the known uncoupler 
dinitrophenol. In contrast, such an increase could not be shown in the presence of 
cimiracemoside A. 
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Incubation State 3 State 4 
Control (1% DMSO) 70±4 9.3±0.4 
Cimicifuga 10 µg/mL 75±7 9.6±0.5 
Cimicifuga 50 µg/mL 70±7 10.3±0.9 
Cimicifuga 100 µg/mL 61±6 8.6±0.7 
Cimicifuga 200 µg/mL 61±3 11.4±0.5 
Cimicifuga 300 µg/mL 56±4* 14.2±1.1* 
Cimicifuga 500 µg/mL 56±3* 21.6±0.9* 
Cimiracemoside A 0.05 µg/mL 73±7 9.3±1.3 
Cimiracemoside A 0.5 µg/mL 86±20 9.6±1.6 
Cimiracemoside A 5.0 µg/mL 73±15 8.2±1.3 
 
Table 1: Effect of cimicifuga racemosa on mitochondrial oxidative metabolism. L-Glutamate (20 
mmol/L) was used as a substrate. Oxygen consumption by freshly isolated rat liver mitochondria was 
determined using an oxygen electrode as described in methods. Oxygen consumption is expressed as 
natoms/min/mg mitochondrial protein. Data are presented as mean±SEM, n ≥4 individual 
observations. * P < 0.05 vs. control incubations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Oxygen consumption in the presence of L-glutamate (20mmol/L) as a substrate and of the 
F1F0-ATPase inhibitor oligomycin (5 µg/mL). In the presence of oligomycin, any increase in oxygen 
consumption has to be due to uncoupling of the respiratory chain, since ADP cannot be 
phosphorylated to ATP. Cimicifuga extract starts to uncouple oxidative phosphorylation at a 
concentration of 300µg/mL, which is in accordance with state 4 oxidation rates shown in Table 1. In 
contrast, cimiracemoside A does not act as an uncoupler. Dinitrophenol was used as a positive 
control. Results are expressed as mean ± SE of 4 determinations. **P < 0.01 vs. control incubations. 
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Since impairment in mitochondrial function can be associated with increased 
production of ROS (Kaufmann et al., 2005; Kaufmann et al., 2006), the redox status 
of HepG2 cells was assessed by determining their glutathione content. However, 
neither raised GSSG levels, nor an increased GSSG/GSH ratio were detectable in 
the presence of cimicifuga extract up to 500µg/mL, suggesting that ROS do not play 
a significant role in cimicifuga hepatotoxicity (data not shown). 
As it is well established that mitochondrial damage can be associated with apoptosis 
and/or necrosis (Wolvetang et al., 1994; Kaufmann et al., 2005; Kaufmann et al., 
2006), we assessed these possibilities using annexin V and propidium iodide staining 
of HepG2 cells. As shown in Figure 6, cimicifuga extract induced a concentration-
dependent increase in early apoptotic and, to a smaller extent, also late 
apoptotic/necrotic cells, starting at a concentration of 300µg/mL. The specificity of 
this mechanism was shown by adding the pancaspase inhibitor zVAD-fmk to the 
incubations, which was able to prevent early (but not late) apoptosis significantly. In 
contrast, the cysteine protease inhibitor zFA-fmk, which does not affect caspases, 
had no effect on apoptosis associated with cimicifuga extract. To further confirm 
these results, Hoechst 33342 stains were performed, which confirmed that treatment 
with cimicifuga extract is associated with apoptosis of HepG2 (data not shown). 
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Figure 6: Early apoptosis (black, grey or shaded columns) and late apoptotis/necrosis (white columns) 
of HepG2 cells incubated with different concentrations of cimicifuga extract and other test compounds. 
After incubation with the test compounds for 24 hours, cells were stained with annexin V and 
propidium iodide and cell fluorescence was analyzed using a cell sorter as described in methods. This 
method allows allocation of cells into the categories living cells, early apoptotic cells and late 
apoptotic/necrotic cells (Kaufmann et al., 2005). While control incubations contain only a small 
percentage of apoptotic or necrotic cells, incubation with FAS ligand (positive control) is associated 
with a significant increase in early apoptotic cells. This increase can be inhibited by co-incubation with 
zVAD, a pancaspase inhibitor. In contrast, the increase is not inhibited in the presence of zFA, a 
cysteine protease inhibitor without activity against caspases. Cimicifuga extract is associated with 
early apoptosis (and to smaller extent also late apoptosis/necrosis) starting at a concentration of 
300µg/mL. Early apoptosis, but not late apoptosis/necrosis, can at least partially be prevented by the 
addition of zVAD, but not zFA. Results are expressed as mean ± SEM of 3 determinations. *P < 0.05, 
**p < 0.01 vs. the respective control incubations. + P< 0.05 vs. the respective incubation containing no 
zVAD. 
 
 
 
In order to discriminate better between late apoptosis and necrosis in the annexin 
V/propidium iodide stain, the ATP content of HepG2 cells treated with cimicifuga 
extract was determined. For the occurrence of apoptosis, normal levels of ATP are 
necessary, whereas low levels of ATP are indicative for necrosis (Leist et al., 1997). 
The ATP levels of the cells treated with cimicifuga extract were not decreased 
compared to untreated control cells, indicating the occurrence of apoptosis and not 
necrosis (data not shown). 
To investigate the possible contribution of mitochondria in the development of 
apoptosis associated with cimicifuga extract, mitochondrial leakage of cytochrome c 
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was investigated using an immunohistological method (Kaufmann et al., 2005; 
Kaufmann et al., 2006). As shown in Figure 7, cimicifuga extract was associated with 
mitochondrial leakage of cytochrome c into the cytoplasm of HepG2 cells, starting at 
a concentration of 200µg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Immuno-cytological staining of cytochrome c in HepG2 cells. Cells (n = 105) were incubated 
for 24 hours with cimicifuga extracts as described in methods. After treatment, they were fixed with 4% 
paraformaldehyde, washed, incubated with anti-cytochrome c antibody, and, after washing, with Cy3 
conjugated anti-sheep IgG (Kaufmann et al., 2005). In control incubations (1% DMSO), cytochrome c 
has a granular structure and does not cover the nucleus (arrows). In the presence of 10 µg/mL 
cimicifuga extract, the pattern of cytochrome c does not change. In the presence of 200µg/mL 
cimicifuga extract, the granular appearance of cytochrome c is changing to more diffuse appearance 
and cytochrome c starts to cover the nucleus (arrows). Some cells are completely covered by 
cytochrome c (arrows). In the presence of 500µg/mL cimicifuga extract, these changes are even more 
accentuated (arrows). In comparison, treatment with 100 µmol/L amiodarone (positive control) is 
associated with complete staining of the cells by cytochrome c, but cells detach from the plate, 
indicating loss of cell integrity. Incubation with the second antibody only was used as a negative 
control. 
 
 
 
 
 
Amiodarone 100 µg/ml2nd antibody onlyDMSO 1%
Cimicifuga 10 µg/ml Cimicifuga 200 µg/ml Cimicifuga 500 µg/ml
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9.5 Discussion 
The main findings in vivo and in vitro were hepatic mitochondrial toxicity, as 
evidenced by microvesicular steatosis and inhibition of β-oxidation, eventually 
leading to apoptotic cell death. Severe inhibition of hepatic mitochondrial β-oxidation 
is associated with cellular accumulation of long-chain fatty acids, e.g. palmitate, 
which, depending on the localization of the defect, may still be activated to the 
respective acyl-CoAs and form triglycerides (Spaniol et al., 2003). Triglycerides can 
be stored in hepatocytes, possibly leading to liver steatosis, or can be exported from 
hepatocytes as VLDL particles (Fromenty and Pessayre, 1995; Fromenty and 
Pessayre, 1997; Spaniol et al., 2003). The microvesicular type of steatosis is thought 
to result from accumulation of triglycerides, acyl-CoAs and long-chain fatty acids due 
to inhibited β-oxidation (Fromenty and Pessayre, 1995; Fromenty and Pessayre, 
1997), which is different from the macrovesicular type of liver steatosis, where 
accumulation of triglycerides is predominant. 
Our studies suggest that inhibition of β-oxidation is the initial hepatotoxic event of 
cimicifuga extract, which eventually may result in apoptosis of the hepatocytes. Since 
long-chain acyl-CoAs accumulate in the cytoplasm of hepatocytes when β-oxidation 
is impaired (Spaniol et al., 2003), these fatty acid metabolites may be associated with 
hepatocellular toxicity. Saturated long chain fatty acids such as palmitate have 
indeed been shown to be associated with apoptosis both in vivo (Feldstein et al., 
2003) and in cell cultures including hepatocytes (Sparagna et al., 2000; Feldstein et 
al., 2003; Wei et al., 2006). Palmitoyl-CoA can induce mitochondrial membrane 
permeability transition, release of cytochrome c into the cytoplasm and apoptosis via 
caspase-dependent pathways (Furuno et al., 2001). Many of our findings, e.g. 
prevention of apoptosis by the pancaspase inhibitor zVAD and release of cytochrome 
c into the cytoplasm HepG2 cells, are in agreement with this mechanism. 
Palmitate and/or palmitoyl-CoA can induce apoptosis by different mechanisms. One 
possibility is increased formation of ceramide, which can induce mitochondrial 
membrane permeability transition (Arora et al., 1997) and is important for apoptosis 
associated with TNF-α (Osawa et al., 2005). However, while the addition of palmitate 
was associated with increased ceramide formation by cultured hepatocytes, inhibition 
of ceramide synthesis did not prevent apoptosis (Wei et al., 2006). In addition, in rat 
neonatal cardiomyocytes, decreased cardiolipin synthesis was found in the presence 
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of palmitate, which was associated with increased release of cytochrome c into the 
cytoplasm and initiation of apoptosis (Ostrander et al., 2001). 
The main constituents of cimicifuga racemosa are triterpene glycosides (e.g. actein, 
deoxyactein, cimifugoside, cimiracemosides), aromatic acids and their derivatives 
(e.g. ferulic acid, isoferulic acid, caffeic acid, fukinolic acid, cinnamic acid esters and 
cimicifugic acid A and B), flavonoids, volatile oils and tannins (He et al., 2006; Jiang 
et al., 2006). The components responsible for the pharmacological activity have so 
far not been identified. Regarding toxicity, Hostanska et al. investigated triterpene 
glycosides and cinnamic acid esters for their ability to induce apoptosis (Hostanska et 
al., 2004b; Hostanska et al., 2004a; Hostanska et al., 2005). Both types of 
substances were found to be associated with caspase-dependent apoptosis in breast 
cancer (Hostanska et al., 2004b; Hostanska et al., 2004a) and prostate cancer cell 
lines (Hostanska et al., 2005). In another investigation, the formation of quinine 
metabolites (possibly generated from phenolic acids and derivatives) has been 
proposed to be the cause of cimicifuga toxicity (Johnson and van Breemen, 2003). In 
our investigations, however, we had no evidence for the development of reactive 
metabolites. Furthermore, in the in vitro study performed by Hostanska et al. 
(Hostanska et al., 2004b), addition of microsomes to the incubations did not increase 
the toxicity of cimicifuga constituents, arguing against the formation of toxic 
metabolites. In order to find out precisely which component of cimicifuga extract is 
hepatotoxic, the most important components of cimicifuga extract would have to be 
studied individually, but most of them are not commercially available. 
To assess whether the toxic concentrations are in the range of the blood 
concentrations reached after ingestion of cimicifuga tablets, a rough estimate can be 
made. Assuming that a preparation containing 5-10 mg ethanolic extract is ingested 
and that the entire extract is absorbed rapidly, a maximal plasma concentration in the 
range of 1.5 -3 µg/mL could be reached (assuming rapid intravascular distribution, a 
plasma volume of 3.5 L and absence of significant metabolism). This value almost 
approaches the concentrations found to inhibit β-oxidation in our in vitro experiments 
(lowest inhibitory concentration 10µg/mL), but is 30 or 150 times lower than the 
lowest concentration associated with cytotoxicity (figure 2) or apoptosis (figure 6), 
respectively. On the other hand, in rats in vivo, microvesicular steatosis of the liver 
was observed at 1000mg extract per kg body weight. Assuming a rapid and complete 
absorption of the extract and a plasma volume of 15mL, the maximal plasma 
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concentration would be in the range of 20mg/mL, a concentration too high to be 
tested in vitro due to solubility problems. These considerations suggest that toxic 
concentrations can most probably not be reached in humans treated with the 
recommended doses. This is in agreement with the toxicity profile of the drug, 
showing hepatic adverse events only in a small fraction of patients, possibly with so 
far unknown risk factors (Dog et al., 2003; Huntley and Ernst, 2003). 
In conclusion, ethanolic cimicifuga extract is associated with hepatic mitochondrial 
toxicity, both in vivo in rats and in vitro using cell cultures and isolated rat liver 
mitochondria. This toxicity is in most patients not clinically relevant but may become 
important in patients with underlying risk factors. 
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10 Conclusion and outlook 
 
Drug-induced liver injury (DILI) is a major health problem that challenges not only 
health care professionals but also the pharmaceutical industry. As a consequence, it 
is also the most frequent reason for the withdrawal of approved drugs from the 
market. Although the exact mechanism of DILI remains widely unknown, it appears to 
involve two pathways – direct hepatoxicity and idiosyncratic hepatic injury. In most 
cases, DILI is initiated by the direct action of a drug, or more often a reactive 
metabolite of a drug (e.g. acetaminophen), and is dose-related. Other hepatotoxic 
drugs induce steatoheptatitis (e.g. ethanol, tamoxifen) or cholestasis (cyclosporine A, 
chlorpromazine). Whereas the above forms of hepatotoxicity are to a large extent 
predictable as a result of pre-clinical toxicology, a second category of drugs can 
cause so-called idiosyncratic hepatic injury where hepatotoxicity develops in only 1 in 
500–50,000 of exposed patients (e.g. phenytoin, isoniazid, valproic acid). Little is 
known about the cause of delayed, non-allergic forms of idiosyncratic hepatotoxicity. 
However, in idiosyncratic allergic drug hepatotoxicity, both the innate and adaptive 
immune system play a determinant role in the pathogenesis of liver injury (Larrey, 
2000; Kass, 2006). 
Another major concern in clinical practice and for the pharmaceutical industry in 
multidrug therapy is the Cytochrome P450 induction-mediated interaction. There are 
two crucial issues associated with CYP induction. First, induction may cause a 
reduction in therapeutic efficacy of co-medications. For drugs whose effect is 
produced primarily by the parent drug, induction would increase the drug’s 
elimination, resulting in lower drug concentrations, and decrease the drug’s 
pharmacological effect. Second, induction may create an undesirable imbalance 
between detoxification and activation as a result of increased formation of reactive 
metabolites, leading to an increase in the risk of metabolite-induced toxicity (Lin and 
Lu, 1998; Lin, 2006).  
 
In this thesis, we present an in vivo model for the investigation of new or approved 
drugs on their hepatotoxic potential, especially drugs initiating idiosyncratic hepato-
toxicity. Our mouse model (juvenile visceral steatosis mouse) is characterized by a 
mitochondrial dysfunction due to impaired hepatic β-oxidation, whereas this pre-
existing mitochondrial disease can be considered to be a risk factor for drug-induced 
hepatotoxicity and may increase susceptibility for the occurrence of severe 
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hepatotoxic reactions. Therefore, this in vivo model can be used to screen drugs for 
their capability to initiate idiosyncratic hepatotoxicity and to evaluate the 
mitochondrial involvement in drug-induced hepatic injury.  
 
Several in vitro models have been established to assess the potential of CYP 
induction, including liver slices, immortalized cell lines, and primary human 
hepatocytes (Silva et al., 1998; Kostrubsky et al., 1999; LeCluyse, 2001). Among 
these models, we present an immortalized human hepatocyte cell line, namely 
hHepLT5, which is a suitable screening system for pharmacological and toxicological 
properties of drugs. hHepLT5 cells contain CYP1A2 and 3A4 isozymes involved in 
drug metabolism. Furthermore, hepatic cell lines show several advantages compared 
to primary hepatocytes, including maintenance of the activity of major drug-
metabolizing enzymes, permanent availability, constant quality, and cultivability. 
Consequently, hHepLT5 cells are a useful tool to investigate certain pharmacological 
and toxicological aspects, facilitating the prediction of several effects of new drug 
entities.  
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